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Camelids produce IgG isotypes that do not conform to the rules governing 
conventional antibody structures.  Typically, immunoglobulins combine homodimeric 
heavy and light chains to produce characteristic tetrameric structures.  Unlike IgG1, 
the camelid IgG2 and IgG3 isotypes do not incorporate light chains into their 
structures.  These unusual antibodies, generally referred to as heavy-chain antibodies 
(HCAbs), comprise approximately 50% of serum IgGs, compatible with a significant 
role in camelid immunity.  Hitherto, the effector functions of camelid HCAbs remain 
largely undefined primarily due to the dearth of available isotype-specific reagents.  
As it was our objective to investigate camelid HCAbs, we produced and characterized 
monoclonal antibodies that discern among the IgG isotypes produced by both llamas 
and alpacas.  These reagents were employed in affinity chromatography, serologic 
analyses, virus neutralization assays, flow cytometry, and immunohistochemistry to 
differentiate between the B cell sub-populations that synthesize conventional and 
heavy-chain IgGs, determine whether expression of the different IgG isotypes was 
regulated differently, and to investigate the clinical and physiological relevance of 
HCAbs. 
 Our investigations led to the discovery of a novel IgG3 protein, and the 
production of immunological reagents that discern among two conventional IgG1, 
IgG2 and the two IgG3 HCAbs.  We have documented that the B cell sub-populations 
 developed within similar lymphoid compartments during gestation.  At birth, HCAbs 
obtained through colostrum contributed to the passive transfer of immunity that is 
critical in protecting the newborn until maturity of its immune system.  Throughout 
life, the B cell sub-populations continued to occupy similar compartments, although, B 
cells that locate within splenic marginal zones expressed one sub-isotype of IgG1 
exclusively.  Also, follicular B cells within adult, ileal Peyer’s patches expressed only 
the novel IgG3.  In response to pathogen infections, camelid B cells elicited IgG2 to 
helminths and IgG3 to viral infections: IgG1 expression was ubiquitous.  Anti-viral 
IgG2 were induced only by hyperimmunization.  While IgG3 proved to be as potent as 
IgG1 in neutralizing activities, anti-viral IgG2 was ineffective.  The data presented 
here document for the first time a dichotomy in the effector functions of camelid IgG2 
and IgG3 HCAbs. 
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 1
 The Camelids 
Characteristics 
Camelids are socio-economically important animals that are used as pack 
animals, sources of fiber and meat, as well as companion animals.  These animals are 
well adapted for inhabiting extreme environments where nutrient-rich food sources are 
scarce.  Accordingly, camelids are highly efficient at ruminating, even more so than 
ruminants (1).  These animals are often classified as ruminants, which is a misnomer 
as camelids are a distinct group of Artiodactyls.  Apart from the obvious differences in 
physical features, camelids are distinct from ruminants in that they have a three 
compartment stomach rather than four, their dentition is unique in that the upper jaw 
contains a single, isolated incisor, the upper lip is bifurcated and independently 
mobile, and they have padded two-toed feet as opposed to hooves.   
Old World camels have characteristic dorsal humps and represent the largest 
species of camelids, weighing up to ~ 1500 pounds.  The one-humped dromedary 
(Figure 1-1A) may grow to 6 ft 11 inches at the poll (part of the head between the ears) 
while the two-humped Bactrian camel (Figure 1-1B)  is slightly taller and may attain 7 
ft 6 inches.  These animals have wide, padded feet and hairy coats.  In contrast, New 
World camels, which include the guanaco, vicuña, llama and alpaca, are much smaller.  
The two wild species, the guanaco (Figure 1-1C) and the vicuña (Figure 1-1D) are 
similar in coloration but have several distinguishing characteristics.  The guanaco has 
a grey face, and both the tail and ears are longer than those of the vicuña (1).  
Guanacos are slightly taller (~ 3 ft 6 inches at the withers) than the vicuña (~ 3 ft 6 
inches) and heavier (≤ 265 lbs vs. ≤ 200 lbs) (1).  The coats are also dissimilar in that 
the guanaco is double-coated with course guard hairs and a soft undercoat while the 
vicuña lacks guard hairs.  Of the domesticated species, the llama (Figure 1-1E) is 
larger than the alpaca (Figure 1-1F).  In fact the llama is the largest of these species 
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Figure 1-1.  Characteristic features of the Old (A and B) and New (C - F) World 
camelids.  (A) dromedary; (B) Bactrian; (C) guanaco; (D) vicuña; (E) llama, and (F) 
alpaca. 
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 (~ 4 ft at the withers and ≤ 550 lb) while the alpacas are similar in size and weight to 
the vicuñas (1).  The llama is double-coated while the alpaca is not.  In general, 
amongst all the camelid species males are larger than females.  In terms of fiber 
quality, the vicuña has the finest fiber followed by the guanaco, alpaca then llama. 
All the camelids have identical karyotypes (2n = 74) and are capable of 
interbreeding to produce fertile hybrids (2-4).  Anthropogenic and natural 
hybridization have been known to occur with members of the same tribe (see below).  
In addition, it has been proven that it is possible to obtain a fertile offspring from 
hybridization between a guanaco and a dromedary camel (5). 
 
Classification 
The three sub-ordinal clades of Artiodactyla include Ruminantia, Suiformes 
and Tylopoda (Figure 1-2).  The Camelidae is the only extant family of Tylopods; 
Oromerycidae, Protoceratidae, and Xiphodontidae have become extinct.  Originally, 
five sub-families of Camelidae existed; Alticamelinae, Camelinae, Poëbrotheriinae, 
Pseudolabidinae, and Stenomylinae.  Fossil records document that Camelinae was the 
most diverse of the sub-families.  All the species, except members of Camelinae, have 
become extinct.  Camelinae is further divided into three tribes; Lamini, Camelini and 
Camelops.  Species within the latter tribe have all become extinct; however, extant 
species of the Lamini tribe include the wild Lama guanicoë (guanaco) and Vicugna 
vicugna (vicuña), and their domesticated descendants, L. glama (llama) and V. pacos 
(alpaca), respectively.  There is further sub-classification of New World lamoids into 
breeds.  Of the Camelini tribe, it is believed that the Camelus dromedarius 
(dromedary) derived from the C. bactrianus (Bactrian).  Today, a small population of 
wild Bactrian camels dwells within the Gobi Desert; however, wild dromedaries 
became extinct c. 3000 B.C. 
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ORDER: ArtiodactylaORDER: Artiodactyla
SUB-ORDER: SuiformesSUB-ORDER: Suiformes FAMILY: Suidae
Tayassuidae
Hippopotamidae
FAMILY: Suidae
Tayassuidae
Hippopotamidae
SUB-ORDER: RuminantiaSUB-ORDER: Ruminantia FAMILY: Cervidae
Bovidae
Ovidae
Giraffidae
FAMILY: Cervidae
Bovidae
Ovidae
Giraffidae
SUB-ORDER: TylopodaSUB-ORDER: Tylopoda FAMILY: CamelidaeFAMILY: Camelidae
SUB-FAMILY: CamelinaeSUB-FAMILY: Camelinae
GENUS: LamaGENUS: Lama SPECIES: guanicoë
glama
SPECIES: guanicoë
glama
GENUS: CamelusGENUS: Camelus SPECIES: dromedarius
bactrianus
SPECIES: dromedarius
bactrianus
GENUS: VicugnaGENUS: Vicugna SPECIES: vicugna
pacos
SPECIES: vicugna
pacos  
Figure 1-2:  Taxonomy of extant camelids 
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 Origin 
Tylopods emerged in North America circa (c.) 50 million years ago (m.y.a.) 
during the middle Eocene epoch (6).  While the Camelidae line persisted, members of 
Xiphodontidae all became extinct by the Oligocene epoch (c. 35 m.y.a.) (7).  
Mitochondrial DNA analyses suggest that the separation between the Lamini and 
Camelini tribes took place c. 11 m.y.a (8).  Fossil records indicate that Camelinae was 
the only sub-family that emigrated out of North America.  Members of the Lamini 
tribe migrated through the Isthmus of Panama into South America while those of the 
Camelini tribe journeyed west across the Bering Strait into Asia.  The oldest records of 
C. antiquus and C. siwalensis found outside of North America dated from the late 
Pliocene epoch (c. 4 – 3 m.y.a.) and were recovered from Northern India (7).  
Meanwhile, the earliest records of Hemiauchenia, thought to be the direct ancestor of 
Lama and Vicugna, were discovered in Argentina and have been dated from the 
Pleistocene epoch (c. 2 to 3 m.y.a.) (6).  Recent genetic studies using mitochondrial 
and microsatellite DNA confirmed the alpaca to be the domesticated descendant of the 
vicuña and the llama to be that of the guanaco (9).  Domestication of the alpaca and 
llama has been shown to have occurred c. 6000 to 7000 years ago while that of the 
dromedary and Bactrian took place c. 4500 – 5000 years ago (1).   
 
Distribution 
 The Bactrian camels are typically found in cold regions of Eurasia, e.g. China, 
east and central Asia, Mongolia and Russia.  The dromedaries are dispersed 
throughout the deserts of Ethiopia, the Sahelian states, Somalia, Sudan, the 
Mediterranean littoral and northern Kenya. The Bactrian and dromedary are sympatric 
within east and central Asia.  The New World camels are distributed through the High 
Andes of Ecuador, Peru, Bolivia, Chile, and Argentina.  Although Paleolama (also a 
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 descendant of Hemiauchenia) migrated back to North America, all North American 
species have become extinct (6).  Old and New World camelids are found in locations 
outside of the aforementioned countries as a result of importation. 
 
Features of IgG isotypes produced by camelids 
Physical properties 
Antibodies are proteins of the immunoglobulin (Ig) superfamily, which are 
classified according to their heavy chain isotype, i.e. IgM, IgD, IgG, IgE, and IgA.  
Isotypes vary both in structure and function.  Generally, antibodies are tetramers 
comprised of two identical heavy (H) chains (μ, δ, ε, α, or γ) associated with two 
identical light (L) chains (λ or κ).  Each H-chain is comprised of an N-terminal 
variable (VH) domain followed by two or more constant (CH) domains, depending on 
the isotype.  Three genes rearrange to encode the VH domain while only one gene 
encodes the CH domains, and in some isotypes, the hinge region.  Light chains have a 
VL domain and one C λ or Cκ domain.  The antigen-binding site of an antibody is 
formed by the association of VH and VL domains.  The CH domains determine the 
isotype and effector function of the antibody. 
Mammals synthesize one to seven IgG isotypes.  In camelids, three IgG 
isotypes have been described.  IgG1 exhibits the typical antibody structure while, 
IgG2 and IgG3, commonly referred to as heavy-chain antibodies (HCAbs), do not 
incorporate L-chains (10).  The nomenclature of camelid IgGs in no way corresponds 
to that of other species, but instead was originally based on the decreasing molecular 
masses of the γ chains of dromedary IgGs: IgG1 (55 kDa), IgG2 (46 kDa) and IgG3 
(43 kDa) (10).  The current nomenclature of camelid IgGs is based on the biophysical 
properties of the IgG isotypes, e.g. differential binding to protein A and protein G, a 
property exploited to chromatographically separate the three isotypes (10).  Only IgG1 
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 and the IgG3 HCAbs adsorb to protein G; the IgG2 HCAbs do not.  All three IgG 
species bind protein A.  Evidence has been reported that substantiates further 
categorization of camelid IgGs into sub-isotypes based on variation in hinge length 
(11-14). 
There are obvious distinctions between heavy-chain and conventional IgGs.  
Firstly, the CH1 domains that typically form covalent bonds with CL domains have 
been removed, and in some instances have been replaced by extended hinge regions 
(Figure 1-3A and B) (10, 12, 14).  In addition, the variable domains of these HCAbs 
(VHH) have replaced key hydrophobic amino acid residues at the putative VH-VL 
interface with hydrophilic residues in order to confer solubility (15).  Further, the first 
and second hypervariable loops of the VHH domain adopt non-canonical loop 
structures to increase the conformational diversification of these antibodies (16-19).  
Lastly, a single VHH domain comprises the antigen-binding site in contrast to 
conventional immunoglobulins that combine a VH with a VL domain to form the 
antigen-binding site (Figure 1-3C and D) (15, 17). 
Conventional IgG1 antibodies produced by Old and New World camelids have 
similar biophysical characteristics; however, pioneering work in the field identified 
differences in HCAb properties among the species.  Hamers-Casterman et. al (11) 
showed that dromedary  IgG2 HCAb (46 kDa) adsorbed only to protein A while the 
IgG3 (43 kDa) adsorbed to both protein A and G.   In contrast, van der Linden et. al 
(20) demonstrated that protein A-specific llama IgG2 (~ 43 kDa) had a smaller 
apparent molecular mass than IgG3 (~ 46 kDa).  Purification of camel IgGs 
demonstrated that HCAbs constitute up to 75% of serum IgG while llama HCAbs 
constitute between 25 – 45% of serum IgG (10).  
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Figure 1-3.  Structures of camelid IgGs.  (A) Conventional IgG1 is a tetramer 
comprised of homodimeric H- and L-chains. (B) HCAbs are devoid of L-chains and 
the isotypes vary in hinge lengths. (C) Antigen-binding domains typically incorporate 
a VH and VL while HCAbs use only a single VHH to bind separate epitopes (D).  
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 Variable domains 
The wealth of information on camelid V genes has been garnered from 
analysing genomic and cDNA sequences obtained from the dromedary.  Genes 
encoding heavy-chain and conventional antibodies are distinct.  Employing Kabat’s 
numbering system (21), VHH genes can be distinguished from conventional VH genes 
by the occurrence of hallmark Val37Phe or Tyr, Gly44Glu, Leu45Arg or Cys, 
Trp47Gly substitutions (15, 22, 23).  These substitutions, which are present in 
germline genes, occur within the framework two region of the VHH domain.  In VH 
domains, these residues are integral to interactions with VL domains.  Molecular 
evolutionary analyses have revealed that VHH genes evolved from the conventional 
VH genes 82–37 m.y.a., before the divergence of the Camelus and Lama, 
approximately 45–11 m.y.a. (23).  To date, genomic DNA analysis identified 50 VH 
and 42 VHH non-redundant germline genes that are expressed in the camels (22, 24).  
Although over 167 non-redundant cDNA sequences have been described in llamas, so 
far only one VH and five VHH germline genes have been characterized (25).  Ongoing 
studies will likely reveal more germline V genes in llamas.  The dromedary VHH 
genes have been assigned to the VH3 family (11).  Seven sub-families have been 
characterized, five of which have been cloned as rearranged products.  Some of the 
VHH genes from the remaining two sub-families should produce functional HCAbs as 
they incorporate appropriate promoter and recombination signal sequences (22). 
Similar to conventional V genes, VHH genes rearrange with diversity (D) and 
joining (J) genes to produce complete polypeptide domain.  So far, there have been 
one D and six (five in llamas) J gene sequences described in camelids (26, 27).  
Comparative analyses of rearranged genomic sequences indicate a common use of D 
and J genes by both VH and VHH genes suggesting an interspersed organization of 
VH, VHH, D, J and CH genes. 
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 Lastly, hypervariability within VHH domains far exceeds that found in VH 
domains (22).  Both the CDR1 and CDR3 loops in VHH may be longer than those 
found in VH domains (11, 15).  Whereas conventional CDR3 loops average 11 - 14 
amino acids in length in mice and humans, the average length of a CDR3 loop in VHH 
domains is 17 amino acids.  The use of extended, hypervariable CDR3 to generate 
antibody diversity has also been noted in bovines (28, 29).  The presence of extra 
cysteine residues within CDR1 and CDR3 may serve as stabilizers by forming 
interloop disulfide bridges.  Additional cysteine residues are also present in the bovine 
CDR3; however, in contrast to those found in camelid CDR3, these residues form 
intraloop disulfide bridges (29). 
 
Light chains 
 To date, genes encoding L-chains have been documented only in the 
dromedary (30).  The production of both λ and κ L-chains has been confirmed based 
on cDNA sequences.  While only one type of IGKC has been obtained there are at 
least two IGLC.  IGLC2 contains a glycosylation site while IGLC1 does not.  
Southern blot techniques illustrated that IGLC genes recombine with at most 20 VL 
genes, but only a limited number of VK genes are used by IGKC genes (25).  Under 
SDS-PAGE conditions, L-chains resolve as two distinct bands, 27 kDa and 30 kDa.  
Further analyses on the gel-purified proteins revealed that glycosylation of λ2-chains 
(30 kDa) accounted for the retardation in electrophoretic migration.  The 27 kDa band 
contained both λ1- and κ-chains (13, 30).  
 L-chains have been shown to associate with conventional, camelid γ and µ H-
chains (31).  Cross-reactive antisera indicate the presence of IgA; however, there have 
not been any reports of IgD or IgE.  Accordingly, there is no information available 
regarding L-chain association with these isotypes in camelids. 
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 Constant domains 
Constant domains of heavy-chain and conventional antibodies are encoded by 
discrete C γ genes.  In keeping with De Genst et. al, these genes will be named 
according to the ImMunoGeneTics nomenclature system (25).  Genomic and cDNA 
sequence analyses have identified at least six different genes that encode IgG1, IgG2 
and IgG3 in the Camelus and Lama.  In the dromedary, cDNA sequences have been 
obtained for five sub-isotypes; IGHG1A, IGHG1B, IGHG2A, IGHG2C and IGHG3 
(12-14).  In llamas, genomic sequence of a IGHG2B gene substantiates the presence of 
a sixth sub-isotype (11).  The IGHG gene sequences correlating to each sub-isotype 
are quite variable; however, it is within the hinge region that the most variability is 
observed.  As a result, classification into sub-isotypes is determined by the nucleotide 
sequence of the hinges (11).   
The CH genes are comprised of exons that encode the C domains, hinge and 
transmembrane regions.  In conventional IgG, each H-chain has a constant portion that 
exhibits a CH1-hinge-CH2-CH3 organization.  The functional specialization of 
immunoglobulins is attributed to the participation of each CH domain in various 
biological activities (32-34).  The CH1 serves two purposes; the random combination 
with CL drives diversification of the antigen-binding repertoire, and CH1-CL disulfide 
bridge assist in stabilizing the VH-VL interactions.  The hinge is a proline-rich region 
connecting the CH1 and CH2 domains, and which contains essential cysteines that 
facilitate dimerization of the H-chains.  The flexibility of the hinge regions also serves 
to modulate effector functions (35).  The CH2 domains are generally separated in the 
dimer by oligosaccharide side chains.  This makes them rather accessible, allowing 
them to bind elements of the complement system (33, 36).  Amino acid sequences 
within the CH2 and CH3 domains are important in binding Fc-receptors (34, 37, 38). 
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  It has been established that HCAb germline C genes encode a CH1, hinge, 
CH2, CH3, M1 and M2 region (12, 14).  However, the CH1 domain is absent from the 
protein due to post-transcriptional excision of its exon.  A conserved AT mutation 
within the flanking donor splice consensus sequence prevents retention of the CH1 
exon in the mRNA.  The CH2 and CH3 domains are highly homologous across 
isotypes.  Work by Woolven et. al (12) revealed 88 – 98 % and 93 – 96 % identities 
among the CH2 and CH3 exons of the llama IgGs, respectively.  Conversely, the 
hinges of IgG2a, IgG2b and IgG2c contain 35, 29, or 15 amino acid residues, 
respectively, while that of IgG3 contains 12 amino acid residues.  By comparison, the 
conventional IgG1a and IgG1b hinges have 19 or 12 amino acid residues.  The 
effector functions of camelid HCAbs have not been described.  However, conserved 
nucleotide sequences within the CH2 exons predict that these domains may become 
glycosylated, and that they should bind to C1q and FcRs, which suggest that 
conventional IgG effector functions might have been retained by HCAbs (14). 
 
Repertoire diversification and class-switching of HCAbs 
A diverse set of germline VHH, combined with mechanisms of somatic 
diversification generate the repertoire of camelid HCAb specificities.  Comparisons 
between germline and cDNA sequences reveal much higher variability within cDNA 
sequences, implying that somatic hypermutation plays a key role in diversifying the 
repertoire (22).  Extra hypervariable regions are located within extended CDR1 and 
CDR3.  In addition, extra disulfide bridges that link and stabilize CDRs, high 
incidences of nucleotide insertions/deletions within the hypervariably regions, and 
gene conversion contribute to diversification of camelid VHH (22).  In cattle, a limited 
number of VH genes belonging to a single gene family depend on long CDR3s, gene 
conversion and point mutation to enrich the repertoire of antigen specificities (39, 40). 
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 Based on the current understanding of how antibodies maintain specificity of 
their V domains while changing effector function of the C domain, we predict that the 
same events take place in camelid immunoglobulin gene rearrangement.  Indeed, one 
study has identified hapten-specific IgG2 and IgG3 encoded by VHH genes from the 
same sub-family (41).  In addition, HCAb C genes contain the relevant switch 
recombination sequence upstream of their CH1 exon.  This would enable isotype 
switching between the HCAbs; however, the μ-γ switch remains an enigma as no gene 
encoding a μ equivalent of the HCAb has been identified. 
 
Applications of HCAbs 
The features of HCAbs afford them novel properties.  HCAbs have a lower 
molecular mass (100kDa) than conventional antibodies (150kDa), which should 
facilitate tissue distribution.  Whereas conventional antibodies tend to aggregate when 
their L-chains have been removed, HCAbs are soluble.  Solubility results from 
replacement of hydrophobic residues by hydrophilic residues at what would be the 
light/heavy chain interface (11, 24).  HCAbs are bivalent (each VHH domain binds an 
epitope), and capable of binding with nanomolar affinities to antigens, comparable to 
conventional antibodies (15, 42).  Affinity maturation is possible as the VHH genes 
have been shown to undergo hypermutation.  Diversification of VHH genes enables 
HCAbs to obtain a wide repertoire of specificities against protein antigens (20, 43).  
Remarkably, HCAbs induced by complex antigens have been reported to demonstrate 
distinct specificities from conventional antibodies (20, 27, 41). 
 Research conducted on HCAbs has focused mainly on their potential 
application as novel immunological tools.  VHH domains are thermally stable and 
capable of binding antigen at temperatures as high as 90 oC; temperatures at which 
conventional antibodies lose affinity for their antigens (44).  This ability to withstand 
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 high temperatures has been exploited to purify VHH from VH domains and to design 
assays to detect caffeine in hot beverages (45, 46). The VHH domain is comprised of a 
single polypeptide sequence making cDNA cloning and expression in yeast fairly 
uncomplicated.  The purification process is simple and expression yields are high.  In 
addition, the extended hinges associated with VHH serve as stable linkers when 
conjugating to other proteins.  Baral et. al engineered ‘immunotoxins’ by conjugating 
VHH domains, specific for conserved, cryptic trypanosome antigens, with a human 
serum trypanolytic protein.  These were shown to have therapeutic implications for 
African trypanosomiasis (47, 48).  In addition, several investigations document the use 
of VHH-conjugates to effectively target tumour-associated antigens (49-53).  
Rothbauer et. al demonstrated the applications of fluorescence-conjugated VHH 
domains (‘chromobodies’) to conduct in vivo targeting and imaging of intracellular 
antigens in live cells (54). 
 A fascinating feature of HCAbs is their ability to be competitive enzyme 
inhibitors (17, 27, 55-58).  In one study, a substantial proportion of enzyme-specific 
HCAbs (approximately 50%) demonstrated inhibitory activities (59).  Generally, 
inhibition is executed by adopting a paratope structure that mimics the carbohydrate 
substrate, that is, by inserting an extended CDR into the active site of the enzyme (58).  
The ability to inhibit enzyme activity in this manner has not been observed in 
conventional antibodies.   
 
Effector functions of conventional IgG antibodies 
The purpose of immunoglobulins is not simply to bind to antigens.  Depending 
on the nature of the antigen, binding may bring about several different effector 
mechanisms, which serve to limit or contain infections.  It is the Fc portion (heavy 
chain or isotype) of immunoglobulins that dictates the effector mechanism that is 
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 initiated.  For IgG, these mechanisms include the activation of the C′ pathway, 
neutralization of microbes and toxins, opsonization and the induction of antibody-
dependent cellular cytotoxicity (ADCC).  All, except for complement (C′) activation 
requires the binding of Fc to Fc-receptors (FcγR) on effector cells.  Sub-isotypes of 
IgG specialize in distinct effector mechanisms; thus, it is imperative that the correct 
isotype be elicited for an immune response to be effective.  The IgG sub-isotype that is 
induced is determined by the cytokine milieu provided by innate and adaptive 
leukocytes involved in the immune response. 
 
Opsonization 
Opsonization by IgG prepares particulates, microbes and infected cells for 
clearance by phagocytic cells.  In humans, IgG1 and IgG3 serve as effective opsonins 
by binding with high affinities to the FcγRs expressed on phagocytic cells.  The high 
affinity FcγRI, and low affinity FcγRIIA and FcγRIIIB expressed on macrophages and 
neutrophils bind Fc domains of antigen-bound IgG to signal phagocytosis (60-62).  
Low affinity FcγRs bind only immune complexes while high affinity FcγRs bind free 
IgG.  Gene targeted experiments identified FcγRI, when associated with the common 
γ-chain, to be the key receptor involved in FcR-mediated phagocytosis (63).  This 
process involves the mobilization of the cytoskeleton to form pseudopods that engulf 
the target infected cell or microbe (64, 65).  In the phagosomes, destruction is 
facilitated by the release of reactive oxygen intermediates and enzymes (66).   
 
Antibody-dependent cellular cytotoxicity 
IgG can bind to antigens on tumors, infected cells, microbes, and helminths to 
mediate lysis by cytotoxic cells that express FcγR on their surface.  Macrophages, 
monocytes, eosinophils, neutrophils and especially natural killer cells express on their 
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 surfaces receptors that can bind Fc on antigen-bound IgG to facilitate ADCC (67-70).  
Natural killer cells are the primary effectors of ADCC.  In humans, these cells express 
the low affinity FcγRIIC and FcγRIIIB (71).  The binding of Fc to FcγR initiates cell 
signaling resulting in the release of lytic enzymes, granzymes, perforin and tumor-
necrosis factor at the site of Fc-mediated contact.  This may lead to the destruction of 
the target cells via ADCC, a mechanism that is distinct from C′-induced cell lysis.  
IgG-dependent ADCC has been implicated as the effector mechanism involved in 
protective immunity against helminths as well as clearance of bacteria-, virus- and 
parasite-infected cells (72-75).    
  
Complement-mediated effects  
The antibody-dependent activation of C′ proceeds via the classical pathway 
subsequent to the formation of a stable association with C1 (76, 77).  At least two of 
the globular C1q regions of C1 must be bound.  Since IgGs possess only one C1q 
binding site, two or more IgG molecules must be optimally situated to permit 
propagation of the C′ pathway.  In humans, IgG3 is the most effective in activating the 
C′ pathway.  The C′ system has several roles in mediating IgG-dependent effector 
functions.  Fc domains of IgG forming immune complexes are bound by C3b, which 
then binds CR1 receptors on erythrocytes (78, 79).  In the liver and spleen, these 
immune complexes are removed by phagocytic cells without the ultimate lysing of 
erythrocytes.  This prevents the deposition of immune complexes in tissues that is 
responsible for the development of autoimmune diseases such as systemic lupus 
erythematosus (80, 81).  Also, IgG binding to bacteria or viruses can initiate the C′ 
cascade eventually leading to the formation of a membrane-attack complex and cell 
lysis, opsonization or the recruitment of inflammatory cells (82-85).  Overall, C′ 
serves to augment and diversify IgG effector functions (86).   
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 Neutralization 
Neutralization occurs when IgG binds epitopes on toxins and viruses to prevent 
attachment to target cells (87-89).  In the case of virus neutralization, the mechanism 
can be executed in several ways (90).  The attachment process can be abrogated when 
IgG binds to a surface protein, which is responsible for binding the host cell receptor 
(91).  Alternatively, IgG neutralization can act downstream of the attachment process 
by preventing membrane transformation required for binding ancillary molecules on 
the target cell surface (91).  Virus-specific IgGs may also prevent internalization of 
virions by interfering with the endocytic process (91).  Overall, IgG neutralization is 
concentration-dependent and may be enhanced by the activation of the C′ pathway. 
 
B lymphocytes 
Ontogeny 
 Antibodies are produced by B lymphocytes.  Stem cells that are destined to 
become B lymphocytes are produced in the liver during gestation or in the bone 
marrow of adult animals.  Lymphopoeisis of B cells occurs throughout life in humans 
and mice or only during gestation in rabbits and ruminants (92-96).  In some species, 
B cell progenitors leave the bone marrow to undergo development in other lymphoid 
organs.  The Bursa of Fabricius in birds and the gut-associated lymphoid tissues 
(GALT) in rabbits and ruminants function as primary lymphoid organs (40, 97-99).  
Within these organs, B lymphocytes undergo several tightly regulated developmental 
stages during which gene rearrangement occurs in order to diversify the antigen-
binding repertoire.  Presentation of endogenous antigens by stromal cells in the bone 
marrow serves to test receptors expressed on the surfaces of developing B 
lymphocytes (100).  The role of stromal cells in GALT is not clear.  
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  The expression of terminal deoxynucleotidyl transferase and the 
recombination-activating genes (RAG1/2) at the pro-B cell stage enables V(D)J gene 
rearrangement at the H-chain locus (101, 102).  Successful rearrangement of these 
genes is achieved when stable transcripts have been obtained.  Subsequently, the 
rearranged V(D)J exons are transcribed with a µ gene to produce IgM H-chains that 
are transported with surrogate L-chains to the cell surface of pre-B cells to form the 
pre-B cell receptor (pre-BCR) complex with the IgαIgβ chains.  At this stage, the pre-
B cell undergoes the initial checkpoint to ascertain whether the IgM H-chain can 
transmit signals.  Presently, it is not clear whether the signal is ligand-dependent or -
independent; however, the non-immunoglobulin portion within the λ5 region of the 
surrogate L-chain is essential in mediating this signal (103, 104).  The pre-BCRs 
transmit signals into the cells via the IgαIgβ signal transduction molecules, which then 
determines whether gene rearrangement was successful and, hence, the fate of the B 
cell (105).  A cell is positively selected if it has successfully rearranged its H-chain 
genes.  These cells undergo rapid proliferation and appear as large pre-B cells.  Next, 
the quiescent small pre-B cells undergo rearrangement at the L chain locus.  
Generally, the κ chain genes are rearranged before λ genes.  The L-chains are paired 
with IgM H-chains and expressed on the surface of immature B cells to form the BCR 
complex.  At this stage, the cell undergoes negative selection.  If the BCR binds to self 
antigens, the cell may be rescued from apoptosis by undergoing receptor-editing of the 
VL genes.  Conversely, cells that do not bind endogenous antigens are permitted to 
enter the periphery.  Approximately 5–10 % of B cells that are produced leave the 
primary lymphoid organ and enter peripheral circulation. 
 In addition to antigen receptors, there are several molecules that are expressed 
on the B cell surface that correlate to the stage of development (106).  The cell-surface 
receptor tyrosine kinase, Kit, and the interleukin-7 receptor are expressed on the stems 
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 cells through to the late pro-B cell stage.  These molecules are essential in transducing 
signals that induce proliferation.  The expression of CD25 replaces that of Kit until the 
small pre-B cell stage.  Other molecules that are essential to B cell development 
include CD45R (B220) and CD19, which are involved in signal transduction of the 
BCR complex and are expressed from the pro-B cell stage throughout the life of the 
cell.  
 
Sub-populations and their functions  
 Subsequent to egress from the central lymphoid organs, B cells enter the 
periphery and begin a circulatory pattern to different lymphoid organs that depends 
upon its lineage, receptor specificity, and cytokine milieu within the lymphoid organs 
(107).  There are three lineages of B cells: B-1, follicular (FO) B-2 and marginal zone 
(MZ) cells (108, 109).  B-1 cells are a self-renewing population that is produced 
before B-2 B cells by the fetal liver (110).  B1 cells have been shown to produce the 
anti-inflammatory cytokine, IL-10 (111).  In humans and mice, B-1 cells constitute < 5 
% of the B cell population, which is in contrast to rabbits where B-1 cells are the 
predominant population (112, 113).  B1a cells, which express the CD5 antigen, 
produce natural antibodies that bind large, polymeric bacterial antigens (114).  B1b 
cells are induced by bacterial polysaccharide antigens to produce the antibodies that 
are essential in conferring long-lasting immunity (114).  The positive selection that is 
responsible for development and maintenance of B-1 cells takes place in the periphery 
and is thought to be driven by self-antigens (115, 116).  These cells are enriched 
within the pleural and peritoneal cavities, implying a role in defending the body 
cavities against invading pathogens.  
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  The MZ B cells are long-lived B cells that are located within the marginal 
sinuses of splenic white pulp.  In mice, MZ B cells are rather sessile, while human MZ 
B cells recirculate (117).  These cells have a pre-activated phenotype and expand 
rapidly in response to blood-borne antigens and bacteria (109, 118, 119).  It has been 
shown that MZ cells are crucial in immunity to Streptococcus pneumoniae, Neisseria 
meningitides, and Hemophilus influenzae.  Although the repertoire of antigen 
receptors among MZ B cells is quite restricted, these cells recognize T-dependent as 
well as T-independent antigens, and are often involved in the initial non-adaptive 
immune response to pathogens.  Compared to FO B cells, intrinsic features of MZ B 
cells, e.g. higher expression of B7 costimulatory molecules and greater signaling 
through the BCR, make them more efficient at activating naïve T cells (120).  
Generally, MZ B cells undergo extrafollicular response to antigens; however, recent 
studies have shown that these cells can initiate germinal center formation within which 
they undergo somatic hypermutation in response to T-dependent antigens (121).   
 Follicular B cells display a broad receptor repertoire and are the major 
population involved in adaptive immunity.  In mice, after leaving the primary 
lymphoid organ, immature B cells enter the spleen exclusively where they go through 
three distinct transitional stages before developing into mature B cells (122).  The 
subsets of transitional cells are distinguished by the expression of IgM, IgD, CD21, 
CD23 and CD24 molecules (123, 124).  BCR signaling determines whether these cells 
survive passage through the spleen.  Positively selected cells then leave to traffic 
through lymph nodes as mature, naïve B cells.  Within lymph nodes, in response to 
exogenous antigens, FO B cells present peptides on MHC class II to T cells in order to 
receive co-stimulation, instructions, and survival signals required to become activated.  
If the T cell had previously encountered the antigen presented by the B cell, then it 
expresses CD40 ligand and secretes growth factors, which together drive proliferation 
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 and differentiation of the activated B cell (125, 126).  Activated B cells enter the 
follicles (termed germinal centers) to proliferate, undergo class-switching and affinity-
maturation of their receptors, and differentiate into long-lived effector (plasma) or 
memory B cells (127).  Memory B cells recirculate while plasma cells migrate to and 
reside within bone marrow (128).   
 
Research objectives 
Studies being conducted on the unusual HCAbs produced by camelids focus 
mainly on exploiting their features for biotechnological purposes.  Little work has 
been done to elucidate the functions of these antibodies within the animals that 
produce them.  The purpose of this thesis research was to contribute to the knowledge 
of camelid HCAbs by illuminating their role in immunity, and by describing the 
ontogeny of the B cells that produce them.  To achieve this, we first had to produce 
and fully characterize isotype-specific mAbs that distinguished the different IgG 
species produced by llamas and alpacas.  Such reagents had not been prepared 
previously.  These mAbs were subsequently used in various experiments designed to 
address specific questions about camelid immunity.  Firstly, to investigate whether 
different HCAb classes were induced by distinct pathogens, we compared the IgG 
profiles elicited during nematode and viral infections.  Next, we investigated the 
functional properties of HCAb isotypes by testing their abilities to neutralize virus and 
mediate Fc-dependent enhancement of virus infectivity.  To evaluate HCAbs in a 
clinical and physiological context, the mAbs were used to measure IgGs in body 
fluids.  Lastly, to describe the life history of the cells that produce HCAbs, B cells in 
tissues from fetal, neonatal and adult camelids were phenotyped using flow cytometry 
and immunohistochemistry analyses.
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CHAPTER 2                                                                               
Application of Monoclonal Antibodies to Functional and Comparative 
Investigations of Heavy-Chain IgGs in New World Camelids1 
 
 
 
 
 
 
 
 
 
 
                                                 
1Lisa P. Daley, Lucille F. Gagliardo, Michael S. Duffy, Mary C. Smith, and Judith A. Appleton. 2005. 
Application of monoclonal antibodies in functional and comparative investigations of heavy-chain 
immunoglobulins in new world camelids. Clin Diagn Lab Immunol 12:380-386. 
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 Abstract 
 
Of the three IgG isotypes described in camelids, IgG2 and IgG3 are distinct in 
that they do not incorporate light chains.  These heavy-chain antibodies (HCAbs) 
constitute approximately 50% of IgG in llama serum and as much as 75% of IgG in 
camel serum.  We have produced isotype-specific mouse monoclonal antibodies 
(mAbs) in order to investigate the roles of HCAbs in camelid immunity.  Seventeen 
stable hybridomas were cloned, and detailed characterization was performed for three 
mAbs that were specific for epitopes on the γ chains of llama IgG1, IgG2 or IgG3.  
Affinity chromatography revealed that each mAb bound its isotype in solution in 
llama serum.  The antibodies bound to the corresponding alpaca IgGs, to guanaco 
IgG1 and IgG2, and to camel IgG1.  Interestingly, anti-IgG2 mAbs bound three heavy-
chain species in llama serum confirming the presence of three IgG2 sub-isotypes.  
Two IgG2 sub-isotypes were detected in alpaca and guanaco sera.  The mAbs detected 
llama serum IgGs when bound to antigen in ELISA, and were used to discern among 
isotypes induced during infection with a parasitic nematode.  Diseased animals, 
infected with Parelaphostrongylus tenuis, did not produce antigen-specific HCAbs; 
rather, they produced the conventional isotype, IgG1, exclusively.  Our data document 
the utility of these mAbs in functional and physiologic investigations of the immune 
system(s) of New World camelids. 
 
Introduction 
The discovery of camelid IgGs that violated established rules governing the 
structure of antibodies was described in 1993 (12).  Unlike their conventional IgG1 
counterpart, camelid IgG2 and IgG3 do not associate with light chains and are called 
heavy-chain antibodies (HCAbs) (Fig. 2-1A).  Genomic and/or complementary DNA 
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 sequences have been obtained for six γ constant (Cγ) genes: Cγ1a and Cγ1b for IgG1, 
Cγ2a, Cγ2b, and Cγ2c for the IgG2 HCAb, and Cγ3 for the IgG3 HCAb (20,22,35,38).  
The Cγ2b gene was identified in genomic clones prepared from llamas (38) and has 
not been described in other camelids.  Variation in masses among the IgG2 sub-
isotypes is predicted from variability in the lengths of exons encoding the hinge 
regions.  Extended hinge regions, deletion of the CH1 domain, and amino acid 
substitutions in the V domain that make it more hydrophilic, promote the flexibility 
and solubility of HCAbs (5,19,21,31,35).  These properties may expand the antigen-
binding repertoire of the immune system by enabling HCAbs to bind otherwise 
inaccessible epitopes.  Given their unusual physical properties, it seems likely that 
HCAbs will play a novel role in immune defense.  
Investigations of camelid antibodies have focused largely on manipulating or 
mimicking the architecture of the variable domains of the HCAbs (VHH) for 
application to medical therapy and biotechnology (4,18,24,30).  Unlike conventional 
antibodies, HCAbs use a single VHH to bind an epitope.  The absence of the light 
chains variable domain is compensated by extended complimentarity determining 
regions (CDR) that provide an adequate antigen-binding surface and demonstrate 
affinities comparable to conventional antibodies (5,28).  An exceptional property of 
HCAbs, which has fueled research activity, is their ability to inhibit enzymes by 
inserting an extended CDR into the active site (17,32).  This property has not been 
observed in conventional antibodies.  The aggregate physical and binding 
characteristics of HCAbs, along with the ease of production of recombinant, active 
VHH in the yeast system (10,34), have prompted researchers to explore their use as 
immunological tools.
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Figure 2-1.  (A) Structure of camelid IgGs. (B) Top: Coomassie blue-stained SDS-
PAGE of purified llama IgG isotypes resolved under non-reducing and reducing 
conditions. (a and b) IgG1 and IgG3 (eluted from protein G); (c): IgG2 (eluted from 
protein A). Bottom:  Western blot of gels identical to Coomassie stained gels 
developed with polyclonal anti-llama IgG (H + L). Molecular masses (in kilodaltons) 
of protein standards run in parallel are indicated. 
40 
There are three published reports of the involvement of HCAbs in camelid 
immunity, specifically, in the response to trypanosome infection and to immunization 
with bacterial proteins (12,30,33).  The production of IgG isotypes in response to 
infection with parasitic nematodes has not yet been investigated.  A limiting factor for 
investigations into camelid immunity has been a shortage of well-characterized, 
isotype-specific immunological reagents. 
Currently, polyclonal antibodies that react broadly with camelid IgGs are 
available from commercial sources.  Monoclonal antibodies (mAbs) specific for 
dromedary (Camelus dromedarius) IgG1 and IgM have been produced and 
characterized (1).  At this time, analysis of lamoid HCAbs can be conducted only on 
chromatographically separated immunoglobulin fractions.  The application of isotype-
specific mAbs in experimental and diagnostic assays will facilitate direct assessment 
of the composition and specificity of the lamoid IgG response to infection.  Results of 
such assays will engender better understanding of the roles of HCAbs in immune 
defense. 
Here we describe the production and characterization of mAbs specific for 
conventional and heavy-chain isotypes of llama IgG.  Seventeen stable hybridomas 
were cloned, and detailed characterization was performed for three mAbs that were 
specific for epitopes on the γ chains of llama IgG1, IgG2 or IgG3 fractions purified on 
Protein A and Protein G.  The antibodies bound to the corresponding alpaca IgGs, to 
guanaco IgG1 and IgG2, and to Bactrian IgG1.  Anti-IgG2 mAbs bound three heavy-
chain species in llama serum confirming the presence of three IgG2 sub-isotypes.  
Two IgG2 sub-isotypes were detected in alpaca and guanaco sera.  The mAbs detected 
llama serum IgGs when bound to antigen in ELISA, and were used to discern among 
isotypes induced during infection with a parasitic nematode. 
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 Materials and Methods 
Animals and sera.  BALB/c mice were obtained from the Jackson Laboratory 
(Bar Harbor, Maine) and housed in the James A. Baker Institute vivarium according to 
the guidelines of the American Association of Accreditation of Laboratory Animal 
Care.  Blood samples were obtained by jugular venipuncture from selected camelids 
(one healthy and four diseased llamas, and one healthy alpaca, guanaco, and Bactrian 
camel) that were brought into the Cornell University Hospital for Animals or 
examined by the ambulatory service.  Serum was separated by centrifugation and 
stored at -20oC.  Infection with P. tenuis was confirmed in diseased llamas by 
observation of nematodes within the central nervous system during necropsy.  Sera 
from llamas in Pullman, Washington, an area non-endemic for P. tenuis, were kindly 
provided by Dr. William Foreyt of Washington State University. 
 
Antibodies.  Polyclonal goat anti-llama IgG (H+L) conjugated to horseradish 
peroxidase (HRP) (Bethyl Laboratories Inc., Montgomery, Texas) was used in ELISA 
and Western blot.  Monoclonal mouse antibodies were detected with HRP-conjugated 
goat anti-mouse antibodies (ICN/Cappel, Aurora, Ohio).  Three mAbs - 27E10 (anti-
IgG1), 19D8 (anti-IgG2), and 8E1 (anti-IgG3) - were selected for use in the serologic 
assays.  An ELISA to determine the isotype of the mAbs employed rat mAbs to mouse 
isotypes and HRP-conjugated mouse anti-rat κ chains antibodies (BD PharMingen, 
San Diego, California).  
 
Purification of llama IgGs. Llama IgG isotypes were purified using affinity 
chromatography as described elsewhere (12,33).  Briefly, serum was first loaded onto 
a Protein G-Sepharose 4B column (Sigma Chemical Co., St. Louis, Missouri), and the 
unbound fraction was collected and loaded on a Protein A-Sepharose 4B column 
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 (Sigma Chemical Co.).  IgG3 was eluted from Protein G with 0.15M NaCl, 0.58% 
acetic acid, pH 3.5, and IgG1 was eluted with 0.1M glycine-HCl, pH 2.7.  IgG2 was 
eluted from Protein A with 0.15M NaCl, 0.58% acetic acid, pH 4.5.  Fractions were 
neutralized immediately with 0.1 M Tris-HCl, pH 9.0. 
 
SDS-PAGE and Western blots.  Serum and chromatographically separated 
IgGs were resolved in discontinuous polyacrylamide gels (16).  Mini-gels were used, 
except for the determination of apparent molecular weights where proteins were 
resolved in standard 15 cm gels.  Samples and molecular weight markers (Bio-Rad 
Laboratories, Hercules, California) were boiled for 7 minutes in sample preparation 
buffer, with or without 2-mercaptoethanol, before loading the gels.  Gels were stained 
with Coomassie blue or were blotted onto nitrocellulose membranes. 
Western blotting procedures were performed at room temperature. Incubation 
periods were 1 hr unless specified otherwise.  Membranes were blocked with 5% skim 
milk in Tris-buffered saline (TBS) and washed with TBS containing 0.05% Tween 20 
and 0.1% bovine serum albumin (BSA; Sigma).  Primary antibodies were diluted in 
blocking solution, and conjugates were diluted in blocking solution containing 10% 
normal goat serum.  Antibody binding was detected with a chemiluminescent substrate 
(ECL reagent, Amersham Pharmacia Biotech, Piscataway, New Jersey) and 
autoradiography.  Films were scanned, and images were prepared using Adobe® 
Photoshop® and Microsoft® Powerpoint®. 
 
Production of monoclonal antibodies.  Mice were injected intraperitoneally 
with 100-300 μg of purified llama IgGs mixed in complete Freund’s adjuvant (Sigma).  
One mouse per isotype was injected intravenously with purified IgG in Dulbecco’s 
phosphate-buffered saline (DPBS) 30 days post immunization and killed three days 
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 later.  Spleen cells were fused with mouse myeloma SP2/0 cells (American Type 
Culture Collection, Rockville, Maryland) according to Kohler and Milstein (15). 
Culture supernates were screened by ELISA for selective binding to one of the 
three llama IgG isotypes.  Plates were coated at 4oC, and other procedures were 
conducted at room temperature.  Well volume was 25 μl.  Wells of polyvinyl 96-well 
microtiter plates (Costar, Cambridge, Massachusetts) were coated overnight with 
llama IgG1, IgG2 or IgG3 in 10% DPBS (1 μg/ml).  Wells were blocked 1 hr with 
DPBS containing 0.05% Tween 20 and 5% skim milk then incubated 1 hr with 
supernatants diluted 1:10 in blocking solution.  Wells were washed five times with 
0.05% Tween 20, DPBS and incubated 1 hr with HRP-conjugated goat anti-mouse 
(0.6 μg/ml) in blocking solution containing 10% normal goat serum.  Binding was 
detected with 3,3′,5,5′-tetramethylbenzidine substrate (KPL, Gaithersburg, Maryland) 
and stopped after 30 minutes with 1M H3PO4.  Optical density readings were taken at 
450 nm using a microplate reader (Biokinetics Reader, EL340; Bio-Tek Instruments, 
Winooski, Vermont). 
Hybridomas that secreted mAbs specific for one llama IgG isotype were 
selected and cloned by limiting dilution.  Hybridomas producing mAbs that were 
selected for further characterization were expanded using the VectraCell system 
(BioVectra, Oxford, Connecticut).  MAbs were purified from culture supernatants by 
affinity chromatography using Protein G Sepharose-4B (Sigma) on an FPLC system 
(ÄKTA, Amersham Pharmacia Biotech Inc., Piscataway, New Jersey) according to 
manufacturer’s instructions. 
 
Isotyping the mAbs.  A modified version of the ELISA protocol used for 
screening the hybridomas was developed to determine the isotypes of the mAbs.  
Bound mAbs were detected with rat monoclonal antibodies to mouse isotypes diluted 
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 1 μg/ml in blocking solution, followed by HRP-conjugated mouse anti-rat κ chains at 
2 μg/ml in blocking solution with 10% normal mouse serum. 
 
Pepsin digestion of llama IgG1.  Purified IgG1 was dialyzed against 0.2 M 
sodium acetate buffer, pH 4.5 and adjusted to 2 mg/ml.  Crystallized pepsin (Sigma) 
was dissolved in the same buffer (1 mg/ml), and digestions were performed at a ratio 
of 1 μg enzyme to 20 μg antibody.  After 1, 2, 4, 6, 12, 24, and 48 hrs in a 37oC water 
bath, digestion reactions were stopped by the addition of 40 μl of 2 M Tris base.  
Fractions were resolved by SDS-PAGE in 8% acrylamide mini-gels. Gels were either 
stained with Coomassie blue or Western blotted. 
 
Affinity chromatography of camelid IgGs.  Affinity columns were prepared 
by coupling 10 mg of a mAb (27E10, 19D8 or 8E1) to 1 g CNBr-activated Sepharose-
4B (Sigma) in the presence of 0.1 M NaHCO3, pH 8.0.  Unbound active sites were 
blocked with 0.1 M Tris, pH 8.0 for 2 hrs at 4 oC.  The coupled gels were washed 
alternately with 0.1 M acetate buffer, pH 4.0 and borate buffered saline (BBS), pH 8.5.  
Columns were loaded with 1 ml llama, camel, guanaco or alpaca serum and washed 
with BBS.  Bound IgGs were eluted from the columns with 0.1M glycine-HCl buffer, 
pH 2.7, into tubes containing 0.1 M Tris-HCl, pH 9.0, and evaluated by Western blot. 
 
Detection of llama IgGs specific for P. tenuis antigens.  The ELISA protocol 
detailed above was modified to detect llama IgGs specific for the recombinant P. 
tenuis aspartyl protease inhibitor, rPt-API.  Preparation of the rPt-API has been 
described elsewhere (7).  Plates were coated with 4 μg/ml r-Pt-API.  Llama sera were 
diluted 1:100 and added to triplicate wells.  Wells were incubated with the 27E10, 
19D9 or 8E1 mAbs (5 μg/ml) or HRP-goat anti-llama antibodies (1 μg/ml) diluted in 
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 blocking solution.  Bound mAbs were detected with 5 μg/ml HRP-conjugated goat 
anti-mouse antibodies diluted in blocking solution containing 10% normal goat serum.   
 
Statistical analysis.  ELISA data from groups of infected and uninfected 
llamas were evaluated by analysis of variance.  Values were considered statistically 
significant when p < 0.05. 
 
Result 
Purification and characterization of llama IgGs.  Affinity chromatography, 
using Protein A and Protein G, was carried out in order to purify the isotypes of llama 
IgGs.  As reported previously (33), llama IgG1 and IgG3 bound to Protein G and 
Protein A while IgG2 bound only to Protein A.  Comparing Coomassie blue-stained 
gels (Fig. 2-1B; Panels i and ii) with Western blots (Fig. 2-1B; Panels iii and iv) 
confirmed that eluted proteins were llama IgGs.  Multiple bands were observed in 
fractions resolved under non-reducing conditions.  The majority of the proteins of 
greater mobility were bound by polyclonal goat anti-IgG (Fig. 2-1B, Panel iii), 
suggesting the occurrence of mild protein degradation during storage of samples.  In 
each non-reduced preparation, a single band migrated between the 66.2 kDa and 45 
kDa molecular weight standards (Fig. 2-1B; Panel iii), compatible with the masses of 
the corresponding monomeric heavy chains.  The IgG3 fraction eluted from Protein G 
was contaminated with IgG1 (Fig. 2-1B, Panel iii, Lane b).  IgG2 co-eluted with an 80 
kDa protein from the Protein A column (Fig. 2-1B, Panel ii, Lane c).  This protein was 
not detected by the anti-llama IgG conjugate (Fig. 2-1B; Panel iv, Lane c). 
Under reducing conditions, IgG1 was resolved into light chains (22.7 kDa) and 
γ1 heavy chains (49.4 kDa) (Fig. 2-1B, Panel iv, Lane a).  The IgG3 preparation was 
reduced to one dominant heavy chain species of 42.1 kDa (Fig. 2-1B, Panel iv, Lane 
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 b).  The IgG2 preparation was reduced to one dominant heavy chain species of 40.9 
kDa (Fig. 2-1B, Panel iv, Lane c).  Contaminants and degradation products were not 
evident in reducing gels.  The three fractions were used to immunize Balb/c mice for 
isotype-specific mAb production.  Because the preparations were known to be 
heterogeneous, the screening procedure for each fusion was designed to reduce the 
likelihood that cross-reactive antibodies would be selected. 
 
Production of monoclonal antibodies.  Supernatants from fusion plate wells 
were tested by ELISA against all three preparations of llama IgG.  Thirty-four 
hybridomas were found to secrete antibodies reactive primarily with only one 
preparation.  Seventeen stable cell lines were cloned to purity: five that secreted mAb 
that bound IgG1, and six each that bound IgG2 or IgG3.  Four of the 17 mAbs were 
mouse IgM and were not pursued.  The remaining 13 mAbs were mouse IgG1, IgG2a 
or IgG2b.  The binding of these 13 mAbs with Protein A/G-purified llama IgGs are 
summarized in Fig. 2-2.  Antibodies 27E10, 19D8 and 8E1, were selected for further 
characterization based on their overall high reactivity with llama IgG1, IgG2 and 
IgG3, respectively. 
 
Specificities of mAbs for immunoglobulins in Western blot.  In order to 
confirm that the IgG1 epitope bound by 27E10 was in the heavy rather than the light 
chain, Protein G purified IgG1 was cleaved with pepsin, and the fragments were 
assayed in Western blot.  Digestion of IgG1 for 6 hrs yielded an array of fragments as 
well as residual whole IgG1 (Fig. 2-3A).  27E10 bound whole IgG1 as well as F(ab′)2  
fragments, but did not bind Fab- or Fc-like fragments (Fig. 2-3B).  Thus binding to 
IgG1 by 27E10 appeared to be dependent upon the presence of the hinge region.  
Further, the antibody did not bind Fab/c-like fragments (Fig. 2-3B) or reduced IgG1 
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Figure 2-2.  Reactivities of mouse mAbs with affinity-purified llama IgGs in ELISA: 
(A) IgG1; (B) IgG3; (C) IgG2. Twofold dilutions of supernatants were tested in 
triplicate wells against purified IgGs. Bound mAbs were detected with HRP-goat anti-
mouse IgG. Columns represent mean optical densities for three replicate wells ± 
standard deviation of the mean (I bars). Asterisks denote mAbs selected for further 
evaluation.
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(data not shown) compatible with a requirement for intact disulfide bridges and stable 
tertiary and quaternary structure in the hinge region.  Our data support the conclusion 
that 27E10 binds within the CH1/hinge/ CH2 region of IgG1. 
The 19D8 and 8E1 mAbs bound to IgG2 and IgG3, respectively, in Western 
blots when used at high concentrations (20-80 μg/ml) (data not shown).  These 
concentrations were 20-80 fold that of normal working concentrations for peptide 
specific antibodies, and some cross-reactivity with other IgG isotypes was evident.  
We concluded that the epitopes recognized by these antibodies are not well-preserved 
under the denaturing conditions of SDS-PAGE and Western blotting. 
 
Binding of mAbs to camelid IgGs in solution.  To ensure that the mAbs had 
been induced against epitopes on native IgGs and not to epitopes exposed during the 
purification process, llama serum was passed over affinity columns prepared by 
coupling CNBr-activated sepharose with 27E10, 19D8 or 8E1.  Each mAb bound the 
predicted llama IgG isotype (Fig. 2-4A).  Unexpectedly, three protein bands were 
observed in the fraction eluted from the anti-IgG2 column, the 40.9 kDa species 
observed in Protein A/G purified IgG2, plus species of 44.1 kDa and 47.2 kDa (Fig. 2-
4A, reduced).  The 8E1 mAb (anti-IgG3) did not bind any of the IgG2 heavy chains in 
Western blot, indicating that they were not IgG3 antibodies that contaminated the 
IgG2 preparation (Fig. 2-5A).  These HCAbs will be referred to as IgG2a, IgG2b and 
IgG2c according to their decreasing molecular weights in order to be consistent with 
the published reports. 
Binding of the anti-llama IgG mAbs to immunoglobulins in sera of other 
camelid species was documented by similar experiments with mAb affinity columns 
(33).  The three mAbs reacted with the homologous isotypes in alpaca serum (Fig. 2-
4B).  Similarly, the 27E10 (anti-IgG1) and 19D8 (anti-IgG2) mAbs bound to guanaco 
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Figure 2-3.  Binding of anti-llama IgG1 mAb (27E10) to fragments of llama IgG1. 
(A) Coomassie stained gel of llama IgG1 digested 0 or 6 hrs with pepsin in acetate 
buffer, pH 4.5. Estimated molecular masses (in kilodaltons) are indicated. (B) Western 
blot showing reactivity of 27E10 (α-1) with llama IgG1, digested 0 or 6 hrs with 
pepsin, developed with HRP-goat anti-mouse antibodies. poly: HRP-goat anti-llama 
IgG (H+L) against pepsin-cleaved IgG1. 
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Figure 2-4.  Specificities of mAbs for native camelid IgGs. The anti-llama IgG1, IgG3 
and IgG2 mAbs, 27E10, 8E1, 19D8, respectively, were coupled with CN-Br activated 
Sepharose-4B and used to purify IgGs from camelid sera. (A) Llama serum; (B) 
alpaca serum; (C) guanaco serum; (D) camel serum. Eluted IgG fractions were 
resolved by SDS-PAGE under non-reducing and reducing conditions and stained with 
Coomassie blue. Estimated molecular masses (in kilodaltons) are indicated. 
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Figure 2-5.  Reactivities of HCAb-specific mAbs with eluates from the anti-IgG3 and 
anti-IgG2 affinity columns in Western blot. Affinity-purified HCAbs from llama (A) 
and alpaca (B) sera were resolved by SDS-PAGE, blotted onto nitrocellulose, and 
developed with anti-IgG2 and anti-IgG3 mAbs (20 μg/ml) or normal mouse serum. α-
3, anti-IgG3 (8E1) mAbs; α-2, anti-IgG2 (19D8) mAbs; -ve, negative control (normal 
mouse serum). Estimated molecular masses (in kilodaltons) are indicated. 
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IgG1 and IgG2; however, 8E1 (anti-IgG3) did not bind a guanaco IgG3 (Fig. 2-4C).  
In contrast with llama, passage of alpaca and guanaco sera over the anti-IgG2 column 
yielded only two IgG2 species: one of 43.3 kDa and another of 40.5 kDa (guanaco) or 
40.9 kDa (alpaca).  Development of a Western blot of the alpaca IgG2 fraction with 
8E1 (anti-IgG3) indicated that neither protein was IgG3 (Fig. 2-5B).  The anti-IgG1 
mAb (27E10) bound to camel IgG1, but neither of the HCAb-specific mAbs bound to 
the homologous isotypes in camel sera (Fig. 2-4D).  In summary, the mAbs bind 
epitopes on native llama and alpaca IgG1, IgG2 and IgG3, guanaco IgG1 and IgG2, 
and camel IgG1. 
Apparent molecular weights of the camelid γ and light chains isolated as 
described above were calculated based on their migration in SDS-PAGE under 
reducing conditions (Table 1). 
 
Evaluation of llama IgGs induced during P. tenuis infection.  Sera from 
llamas resident in areas endemic or non-endemic for P. tenuis were tested by ELISA 
for the presence of parasite-specific antibodies of each IgG isotype.  Polyclonal goat 
anti-llama IgG conjugate was tested in parallel.  All sera tested yielded high OD 
readings with the polyclonal reagent.  Sera from infected/diseased animals could not 
be distinguished from that of a healthy llama from an endemic area, nor from sera of 
animals from non-endemic areas (Figure 6).  The apparent lack of specificity may be 
due to binding of the conjugate to IgM as a result of its specificity for light chains.  
Although the recombinant protein antigen bears a His tag and was affinity-purified by 
Ni-chelation chromatography (7), it was produced in E. coli and may carry trace 
amounts of bacterial protein.  The polyclonal conjugate may bind light chains of low 
affinity, E. coli-specific, or other non-specific, IgM that is likely present in the sera of 
all llamas.  Although there are other possible explanations for the lack of 
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Table 2-1.  Molecular masses (kDa) of camelid IgGs estimated by migration in SDS-
PAGE
a
.  
 
 
ide, 15 cm gels. 
f sera resolved under similar conditions. 
39.0c42.9c23.251.4Camel
42.1c40.543.322.750.8Guanaco
42.140.943.322.549.9Alpaca
42.140.944.147.222.749.4Llama
cbaLH
IgG3IgG2IgG1b
a
10 % acrylam
b
Calculated from Western blot o
c
H, heavy chain; L, light chain. 
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discrimination by the polyclonal reagent (discussed below), our results diminish 
enthusiasm for its use in ELISA. 
In order to determine the isotype composition of the antibody response to a 
parasitic nematode, the ELISA was modified to incorporate the isotype-specific mAbs.  
Serum from the uninfected llama residing in an area endemic for P. tenuis lacked IgG 
specific for rPt-API (Fig. 2-6A).  In contrast, all sera collected from diseased/infected 
llamas contained high concentrations of IgG1 specific for the rPt-API.  Trace 
concentrations of IgG2 were detected in two of these animals.  Because of the high 
prevalence of P. tenuis infection in endemic areas, it is impossible to assert with 
confidence that any llama has not been exposed to the parasite.  For this reason we 
tested sera from healthy llamas obtained from a region free of P. tenuis (Washington, 
USA).  These sera yielded variable results.  Four of seven llama serum samples had 
antigen-specific antibodies; however, instead of IgG1 being quantitatively dominant, 
IgG2 and/or IgG3 were detected in similar concentrations in each sample.  Statistical 
analysis of the ELISA data did not detect significant differences between P. tenuis 
infected and uninfected llama sera.  As described above, the antibodies may be 
specific for bacteria and binding contaminating E. coli proteins in the antigen 
preparation.  Alternatively, the antibodies may be specific for rPt-API but induced by 
similar antigens produced during infection with other parasitic nematodes that are 
prevalent in Washington.  Nematode API show high amino acid sequence similarities 
across genera and are known to be highly immunogenic (7).  Overall, the results show 
that ELISA employing isotype-specific reagents will improve and enrich the 
information afforded by such assays, yet the selection of the target antigen remains 
critical for interpretation of the data.  
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Figure 2-6.  Detection of rPt-API-specific IgG isotypes in llama sera by ELISA. (A) 
Llamas from a P. tenuis-endemic area (New York, USA). Sera from diseased llamas, 
confirmed to be P. tenuis-infected, contained predominantly IgG1 specific for rPt-API. 
No antigen-specific IgG isotypes were detected in the uninfected llama serum. 
Polyclonal goat anti-llama IgG (H + L) did not discern infected from uninfected 
llamas. (B) Llamas from P. tenuis-free area (Washington, USA). Cross-reactive IgG1 
as well as IgG3 and/or IgG2 were detected in sera from uninfected llamas. The 
polyclonal goat antibodies yielded consistently high readings for all seven sera. 
Columns represent mean optical densities. of sera diluted 1:100 (tested in triplicate) ± 
standard deviation (T bars). 
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Discussion 
We prepared mAbs specific for IgG1, IgG2 and IgG3 of llamas.  Each mAb 
bound its soluble, native IgG and, when used to prepare affinity columns, afforded an 
improvement over previously described Protein A/G affinity methods for separation 
and purification of the isotypes (12).  In addition, the mAbs were effective in ELISA 
for detection of antigen-specific antibodies.  Finally, an IgG2-specific mAb bound 
three discrete llama heavy chains, confirming the existence of three IgG2 isotypes in 
the llama, as had been inferred from DNA analyses (35,39).  
 Camelids emerged in North America during the Eocene epoch some 45-40 
million years ago (m.y.a.); however, the Camelini and Lamini divergence did not 
occur until 11-9 m.y.a. (36,38).  Subsequently, the cameloids migrated across the 
Bering Strait, while the lamoids migrated towards South America.  To date, the one-
humped dromedary (Camelus dromedarius) is native to the Arabian Desert while the 
two-humped Bactrian (Camelus bactrianus) is found in Asia.  The lamoids include 
guanacos (Lama guanicoe), llamas (Lama glama), alpacas (Lama pacos), and vicuñas 
(Vicugna vicugna), and are indigenous to South America.  Domestication of llamas 
and alpacas is estimated to have occurred 5500 to 6000 years ago (37).  The camelids 
that remained in North America became extinct and llamas from South America were 
reintroduced in the late 1880s.  
Microsatellite and mitochondrial DNA analyses have revealed genetic 
similarity between vicuña and alpaca and between guanaco and llama, suggesting that 
the alpaca was domesticated from the vicuña and the llama from the guanaco.  It has 
been proposed that alpaca should be reassigned to the genus Vicugna (Vicugna pacos) 
(37).  Most modern day alpaca and llama carry both guanaco- and vicuña-like DNA 
reflecting a high incidence of hybridization between the domestic species.  It has been 
estimated that as many as 80% of modern day alpaca are hybrids (37).  Although a 
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 likely aim of hybridization was to improve fiber quality in larger animals, fiber quality 
in domestic species has declined.  Efforts are underway to improve genetic purity and 
fiber quality in alpaca (37).  
We evaluated binding of the mAbs to IgGs of Old and New World camelids.  
Vicuña are both wild and endangered; we did not have access to sera from that 
species.  The anti-IgG1 mAb bound its isotype in all camelids tested, including C. 
bactrianus. Among the New World camelids, IgG3 was not detected by the 
appropriate mAb in guanaco.  Only two IgG2 sub-isotypes were detected in alpaca and 
guanaco, compared with three in llama.  Hybridization in the New World camelids 
confounds any attempt to interpret these results in evolutionary terms.  Although we 
tested sera from several animals in this study, each alpaca and llama was defined as 
such by phenotype rather than genotype.  Expanded testing on larger numbers of llama 
and alpaca including animals of defined genotype will be important for validation of 
the specificities of mAbs against IgG2 and IgG3. 
 The importance of immunoglobulins to the health and well-being of camelids 
is documented by the high mortality among neonates that fail to receive adequate 
colostral antibody (11).  The contribution of HCAbs in passive transfer of immunity to 
neonates is unknown.  Furthermore, little is known of the functional contributions of 
camelid IgGs to immune defense.  Camelids have specific pathogens, suffer from 
common diseases of ruminants, and, as in the case of foot and mouth disease, are 
resistant to some pathogens (2,6,8,25,27).  Camelid HCAbs may have distinct roles in 
fighting infections.  Their more discrete antigen-binding domains, extended CDRs, 
and increased tissue accessibility, enable HCAbs to bind epitopes otherwise 
inaccessible to conventional antibodies.  In addition, HCAbs have been shown to 
inhibit enzymes (17,32).  The significance of these properties in immune defense, and 
the nature of the stimuli that induce production of HCAbs, are unknown.  
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  Parelaphostrongylus tenuis is a cause of morbidity and mortality in llamas and 
alpacas (9,26).  Disease results from physical trauma and cellular infiltration into the 
parenchymal tissues of the central nervous system induced by migrating worms.  We 
found that infections of varying duration stimulated the production of antigen-specific 
IgG1 in four animals.  HCAbs were not prominent in these immune responses.  All 
four animals were ill and eventually died or were euthanized, implying that the 
immune response induced was not protective.  However, our conclusions are based on 
the results obtained with a single protein antigen, and it will be important to 
corroborate the data obtained for Pt-API with other antigenic proteins and glycans. 
 Studies in other species have shown that the specificity and sensitivity of a 
serologic test may be increased when designed to detect a particular IgG isotype.  For 
example, detection of IgG4 antibodies specific for recombinant antigens of Fasciola 
hepatica, Angiostrongylus cantonensis, or Loa loa increases the sensitivity and 
specificity of assays for these infections in humans (13,14,23).  Similarly, by using 
isotype-specific reagents, we reduced high background readings obtained using pan-Ig 
antibodies, and demonstrated that P. tenuis-infected llamas mounted an anti-Pt-API 
response that was overwhelmingly IgG1.  The utility of this finding was complicated 
by our observation that four sera from llamas in a non-endemic area had antigen-
specific IgG1, IgG2, and in some cases, IgG3.  Although these animals were 
dewormed every six months, they were reared conventionally and were likely exposed 
to other parasitic nematodes (William Foryet, personal communication).  Ostertagia 
ostertagi is a common parasitic nematode of llamas and produces an API that is 74% 
identical in amino acid sequence to Pt-API.  Infection with this or some other 
nematode may have induced the antibodies detected.  The difference in isotype 
representation in sera of the diseased vs. non-endemic llamas may be due to the site of 
parasite residence (e.g. CNS for P. tenuis vs. gastrointestinal tract for O. ostertagi) or 
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 other influences.  To address the issue of cross-reactivity, we are seeking other, 
potentially unique, P. tenuis antigens for application in serologic tests. 
 In summary, we have produced and characterized mAb reagents specific for 
heavy-chain and conventional IgGs of llamas.  The mAbs are readily applied in 
serologic assays and affinity chromatography, and should be useful in quantitative 
assessments of IgG isotypes in blood, colostrum, and other body fluids.  Their 
application in identifying IgG isotypes induced during protective and non-protective 
immune responses to different types of pathogens will improve our understanding of 
immune defense in New World camelids and should aid in the design of effective 
vaccines. 
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Participation of Camelid Heavy-Chain Antibodies in Immune Responses 
to Nematode and Viral Pathogens2 
 
 
 
 
 
 
 
 
 
 
                                                 
2Lisa P. Daley, Michelle A. Kuztler, Barbara W. Bennett, Mary C. Smith, Amy L. Glaser and Judith A. 
Appleton.  Participation of camelid heavy-chain antibodies in immune responses to nematode and viral 
pathogens. Manuscript in preparation. 
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 Abstract 
Naturally occurring IgGs devoid of light chains are produced by Camelids.  
These heavy-chain antibodies (HCAbs) have largely undefined effector functions.  In 
order to describe the contributions of HCAbs to immune defense, HCAbs and 
conventional IgG1 were assayed in sera from animals infected with a nematode, 
Parelaphostrongylus tenuis or with West Nile virus (WNV).  IgG1 dominated the 
responses to nematode and viral proteins.  Nematode antigens induced IgG2, but not 
IgG3 HCAbs, while WNV infection induced only low levels of HCAbs.  In contrast, 
IgG3 was readily induced by vaccination with WNV.  IgG2 HCAbs were produced 
during the anamnestic response.  When purified IgGs were tested in plaque-reduction 
neutralization titer (PRNT) tests, IgG3 demonstrated PRNT activities comparable to 
conventional IgG1.  At the highest concentrations tested, IgG2 demonstrated only sub-
neutralizing activity.  We further investigated whether the IgGs altered virus 
infectivity of alpaca cells that expressed Fc-receptors.  IgG3 and IgG1 enhanced WNV 
infection of macrophages at concentrations below those that effectively neutralized 
virus on Vero cells.  Our data document for the first time a dichotomy in the HCAb 
response to viral and nematode pathogens, and a distinction in their virus-
neutralization properties.  This information contributes to the elucidation of the 
immunological role of these atypical IgGs, and has implications for diagnosis, 
prophylaxis, and therapy. 
 
Introduction 
 It has long been established that antibodies combine homodimeric heavy (μ, δ, 
ε, α or γ) and light chains (λ or κ) to form their characteristic tetrameric structures.  
However, camelids produce antibodies that do not conform to this rule.  In addition to 
the conventional IgG1 isotype, the IgG2 and IgG3 isotypes produced by these animals 
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 do not incorporate L-chains into their structures (1, 2).  These unusual IgGs, termed 
heavy-chain antibodies (HCAbs), lack the CH1 domain of the H-chain, which would 
normally form a disulfide bridge with the CL domain to stabilize the heavy/light-chain 
association (3, 4).  This deletion results from a conserved mutation in the flanking 
donor splice consensus sequence that causes post-transcriptional excision of the CH1 
exon.  In addition, the VH of HCAbs (VHH) incorporates mutations that encode 
hydrophilic amino acid residues at the putative heavy/light chain interface that confer 
solubility (5).  To increase diversification of the combining sites, the first and second 
hypervariable loops adopt non-canonical loop structures (6-9).  VHH domains may 
possess extended CDR3s, similar to bovine immunoglobulins, which serve to increase 
the surface area for binding antigens (10).  HCAbs are bivalent, undergo antigen-
driven somatic hypermutation, and exhibit nanomolar binding affinities (6, 11).  The 
composition of HCAbs within serum may be as much as 45 % in Lama spp. and up to 
75 % in Camelus spp., compatible with a significant contribution by these antibodies 
to immune defense (2).   
Despite being discovered over fourteen years ago, very little work has been 
done to elucidate the immunological functions of HCAbs.  For example, it is not 
known how production of camelid IgGs is regulated.  In mice and humans, distinct 
IgG isotypes are elicited by different types of pathogens, and the functions of the 
isotypes are relevant to defense against each pathogen.  There are characteristic IgG 
isotype profiles associated with type 1 and type 2 immune responses that are induced 
by viruses and helminth parasites, respectively.  Unique biophysical properties bolster 
the hypothesis that HCAbs have discrete effector functions.  The effector function of 
an immunoglobulin depends upon the CH2 and CH3 domains.  In llamas, the CH2 and 
CH3 exons are 88 – 98% and 93 – 96 % identical, respectively, across the IgG 
isotypes.  However, IgG3, like IgG1, binds protein G while IgG2 does not (2, 12).  
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 This differential binding of IgG2 and IgG3 to protein G, an FcγRIII orthologue, may 
correlate with effector functions.  Compared with classical antibodies, HCAbs are 
small in structure, having apparent molecular masses of approximately 100 kDa versus 
150 kDa for IgG1, and the VHH domains (approximately 15 kDa) are the smallest, 
natural antigen-binding fragments known to date (2, 13).  The smaller size may render 
HCAbs more diffusible than conventional IgG1, allowing them to bind epitopes that 
would normally be inaccessible.  The structural features of HCAbs suggest that these 
isotypes may have distinct roles in camelid immunity.  Research into camelid antibody 
functions have been greatly hindered by the lack of antibody reagents.  To address 
this, we produced and characterized mAbs that bind specifically to IgG1, IgG2 or 
IgG3 produced by llamas and alpacas (14). 
In this study, we compared the contributions of IgG1, IgG2 and IgG3 in 
immune responses elicited during infections with two pathogens:  the parasitic 
nematode, P. tenuis, and WNV.  Furthermore, we investigated the effector functions 
of virus-specific heavy-chain and conventional antibodies.  Our data indicate that 
IgG2 is distinct from IgG3, both in function and in regulation. 
 
Materials and Methods 
Animals and sera.  In all cases, camelid blood was obtained by jugular 
venipucture into vacutainers containing sodium heparin.  Blood samples from llamas 
infected with P. tenuis were obtained from diseased animals that were brought into the 
Cornell University Hospital for Animals or examined by the ambulatory service.  
Infection with P. tenuis was confirmed in diseased llamas by observation of 
nematodes within the central nervous system during necropsy.  Serum was separated 
by centrifugation and stored at -20 oC.  Sera from llamas in Pullman, Washington, an 
area non-endemic for P. tenuis, were kindly provided by Dr. William Foreyt, 
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 Washington State University.  These animals may have been exposed to P. andersoni 
and almost certainly gastrointestinal nematodes endemic to western Washington.  Sera 
from alpacas that were naturally infected with WNV were obtained during a 
surveillance study conducted in New Jersey.  Sera from WNV-vaccinated alpacas 
were collected as part of a vaccine study (15).  Both sets of samples were kindly 
provided by Dr. Michelle Kutzler, Oregon State University. 
For macrophage cultures, blood was obtained from two mature female alpacas 
owned by the Cornell University Veterinary School.  Animals were housed according 
to the guidelines of the American Association of Accreditation of Laboratory Animal 
Care. 
 
WNV vaccination.  The vaccination protocol has been described elsewhere 
(15).  Briefly, alpacas were vaccinated intramuscularly with 1 ml formalin-inactivated 
WNV vaccine adjuvanted with MetaStim™ (West Nile Innovator, Fort Dodge Animal 
Health).  Alpacas received three vaccinations at 3-week intervals.  Some animals 
received an additional dose of vaccine 1 yr after the third immunization and are 
referred to as “vaccinated/boosted”.  Sera from these animals were collected 4 wks 
after the fourth immunization.  The animals were monitored for local and systemic 
reactions to vaccination.  
 
Antibodies.  Polyclonal goat anti-llama IgG (H + L) conjugated to horseradish 
peroxidase (HRP) (Bethyl Laboratories Inc.) was used in ELISA.  Monoclonal mouse 
antibodies (mAbs) were detected with HRP-conjugated goat anti-mouse IgG (H + L) 
(ICN/Cappel).  The 27E10 (anti-IgG1), 19D8 (anti-IgG2), and 8E1 (anti-IgG3) mAbs 
have been described elsewhere (14). 
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 Recombinant, WNV envelope (E) and nonstructural (NS1 and NS5) 
proteins.  Recombinant proteins were provided by Dr. Amy Glaser, Animal Health 
Diagnostic Center, Cornell University and the preparation protocol will be described 
elsewhere.  Standard coupled reverse transcriptase polymerase chain reaction (RT-
PCR) techniques were used to amplify the NS5, NS1 and E coding sequences from 
WNV RNA, using primers for the genes of interest.  WNV NS5 amplification primers: 
forward, GACGATATCAGGTG GGGCAAAAGGACGCACC, and reverse, 
CTAGTCGACCAGTACTGTGTCCTCA ACCAA; WNV NS1 amplification primers: 
forward, ACGATCTGCAGATAAGCA TTCACTTGTGACTGCAC, and reverse, 
ACGTGATATCCACTGGGTGTGCCATA AACATC; WNV E amplification 
primers: forward, AGCTGATATCTAACTGCCTT GGAATGAGCAAC, and reverse, 
ACGATCTCGAGAGCTATGGACCTATCAC. 
PCR amplified DNA fragments were digested with EcoRV and XhoI and 
cloned into the pTriEx-1 plasmid vector (Novagen) containing the honey bee mellitin 
signal sequence.  Plasmids containing inserts were selected based on restriction 
endonuclease digestion and sequence analysis.  The resulting plasmids were 
designated as pTriEX-WNVNS5, pTriEX-WNVNS1, pTriEX-WNVE.  Baculovirus 
recombinants were prepared by co-transfection of plasmid DNA and BacVector 3000 
DNA (Novagen) and used to infect Sf9 cells.  Virus purified from plaques was assayed 
for expression of the respective proteins by indirect immunofluorescent assay using 
polyclonal anti-WNV murine ascites (NS5) or mAbs against E or NS1 (CDC).  Virus 
expressing WNV proteins was amplified in Sf21 cells. 
Cells were lysed and expressed proteins were purified using nickel affinity 
chromatography (BioRad). Eluted proteins were dialyzed at room temperature in 
phosphate buffered saline (PBS) containing 20% glycerol and stored at -20 °C in 50% 
glycerol, PBS. 
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 Affinity chromatography of camelid IgGs.  IgG isotypes were purified using 
affinity chromatography (mAbs 27E10, 19D8 or 8E1) as described elsewhere (14).  
Purified IgG fractions were dialyzed against Dulbecco’s phosphate buffered saline 
(DPBS) and evaluated for homogeneity by ELISA before use in subsequent assays.  
Briefly, microtiter plates were coated with mAbs (5 μg/ml) specific for each isotype, 
28G4 (anti-IgG1), 16A4 (anti-IgG2) and 2B11 (anti-IgG3).  Wells were blocked with 
5% skim milk, incubated with affinity-purified IgG (1 μg/ml) and bound IgGs were 
detected with HRP-goat anti-llama IgG (0.1 μg/ml). 
 
Detection of llama IgGs specific for P. tenuis.  The ELISA described in 
Daley et. al (14) was modified to detect camelid IgGs specific for P. tenuis third-stage 
larvae (L3).  Soluble antigens were prepared by lysing 100 L3 worms by freeze-
thawing three times followed by sonication and removal of particulates by 
centrifugation.  For all steps, well volumes were 25 µl and plates were incubated 1 hr 
at room temperature unless otherwise specified.  Plates were coated overnight at 4 oC 
with 4 μg/ml soluble L3 antigens in 10 % DPBS then blocked with DPBS containing 
2% skim milk and 0.05% Tween 20.  Plates were washed three times with DPBS 
containing 0.05% Tween 20 after each incubation step, and subsequent dilutions were 
prepared using blocking solution.  Llama sera were diluted 1:100 and added to 
triplicate wells.  Wells were incubated with the 27E10, 19D8 or 8E1 mAbs (5 μg/ml) 
or HRP-goat anti-llama IgG (0.1 μg/ml) as a positive control.  Bound mAbs were 
detected with 5 μg/ml HRP-conjugated goat anti-mouse IgG diluted in blocking 
solution containing 10% normal goat serum.  The assay was developed with 3,3,5,5'-
tetramethyl-benzidine (TMB, KHL) and reactions were terminated with 1M H3PO4.  
Optical density (O.D.) readings were taken at 450 nm wavelengths with a microplate 
reader (Biokinetics Reader, EL340; Bio-Tek Instruments). 
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 Determination of endpoint, serum neutralization titers.  The protocol used 
to determine endpoint, serum neutralization (SN) titers for WNV infected and 
vaccinated alpacas has been described elsewhere (15).  In brief, virus-neutralization 
antibody titers were obtained by incubating two-fold serial dilutions of serum (heat-
inactivated 30 m, 56 oC) for 1 hr with equal volume of WNV (102, 50% tissue culture 
infective dose) and 3% guinea pig complement (C′).  Incubations were conducted at 
37 oC in 5% CO2 and samples were tested in duplicates.  Mixtures were added to equal 
volumes of Vero cell suspensions in wells of microtiter plates, incubated 6 d, and cells 
were examined for cytopathogenic effects (c.p.e.).  Geometric mean titers were 
determined for duplicate samples and endpoint titers were calculated as the inverse of 
the highest serum dilution that inhibited c.p.e. of virus.  A value < 8 was considered as 
negative. 
 
Detection of camelid IgGs specific for WNV proteins.  The ELISA 
described above was modified to detect IgGs specific for WNV.  Plates were coated 
with 5 μg/ml recombinant viral proteins (E, NS1 or NS5).  Sera were diluted 1:100 
and added to triplicate wells.  Wells were incubated with isotype specific mAbs or 
HRP-goat anti-llama IgG.  Bound mAbs were detected with HRP-conjugated goat 
anti-mouse IgG. 
 
Plaque-reduction neutralization assay.  WNV-NY1999 stock were grown in 
Vero cells and frozen at -80 oC until use.  Plaque-reduction neutralization titers 
(PRNT) were determined for heat-inactivated (60 oC, 5 m) alpaca serum or affinity-
purified IgGs.  Incubation periods were 1 hr at 37 oC in 5 % CO2.  Two-fold serial 
dilutions of serum or affinity-purified IgGs were incubated with an equal volume of 
WNV (1 – 2 × 103 plaque-forming units (p.f.u.) per ml) with or without guinea pig C′ 
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 (5 %; Colorado Serum Company).  Vero cell monolayers were grown in 6-well culture 
plates.  Inoculum (100 µl) was added to each well, incubated 1 hr., then monolayers 
were overlaid with medium containing 1% (w/v) low-melting point agarose and 
incubated 4 days.  Plates were stained on day 3 with Neutral red and plaques were 
enumerated on day 4.  Plaque-reduction was calculated as a percentage of plaques 
obtained in the absence of serum or antibodies.  A reduction of 90% (PRNT90%) or 
greater was set as the positive threshold. 
 
Preparation of monocyte-derived cell cultures.  A protocol described by 
Davis et. al (16) was modified to separate mononuclear cells from alpaca blood. 
Heparinized blood was diluted 1:3 in sterile PBS and layered onto density gradients 
(upper gradient - Histopaque® 1077; lower gradient - Histopaque® 1119; Sigma) in 
50 ml polypropylene tubes.  Tubes were centrifuged 700 × g in a swinging bucket 
rotor with the brake off for 1 hr at ambient temperature.  Supernatant was aspirated 
within 0.5 cm of desired layers and discarded.  Mononuclear cells were collected from 
the plasma-upper gradient interface.  Granulocytes (mostly neutrophils) settled at the 
interface between the upper-lower gradients.  Red blood cells pelleted at the bottom of 
the centrifuge tubes.  Cells were washed three times by suspending in PBS and 
centrifuging (250 × g) for10 m at 10 oC.  Viability was estimated with trypan blue in a 
hemocytometer, and cellular composition was evaluated by flow cytometry. 
Mononuclear cells were cultured according to the protocol described by 
Saldarriaga et. al (17) with few modifications.  Pelleted cells were resuspended to a 
final concentration of 2 × 106 cells/ml (containing approximately 4 × 105 
monocytes/ml) in Dulbecco’s modified Eagle’s medium (DMEM; Sigma) 
supplemented with 10% heat-inactivated fetal calf serum (Atlanta Biologicals), 0.5 
mg/ml gentamycin sulfate (Cellgro), 0.25 μg/ml fungizone (Gibco), 100 U/ml 
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 penicillin (Gibco), 0.1 mg/ml streptomycin (Gibco), 2 mM L-glutamine(Gibco), and 
50 μM β-mercaptoethanol (Sigma).  Cell suspensions (1 ml/well) were added to 24-
well tissue culture plates, and incubated at 37 °C with 5% CO2 to allow for adhesion.  
After 24 hours, non-adherent cells were removed. Cultures were maintained by 
replacing medium every four days.  Seeding wells at a density of 4 × 105 mononuclear 
cells generally yielded 1 × 105 adherent macrophages per well at the end of the culture 
period. 
 
α-Naphthyl acetate esterase assay.  To confirm that adherent cells were 
macrophage-like, 8-day old cultures were incubated 5 m with cold Trypsin-EDTA 
(Sigma) to release cells from the surface.  Cells were washed twice in PBS, 
centrifuged (500 × g, 5 m) onto glass microscope slides, and air-dried overnight at 
room temperature.  Staining was performed with the α-naphthyl acetate esterase kit 
(Sigma) following manufacturer’s instructions.  Briefly, cells were fixed for 30 s with 
a citrate-acetone-formaldehyde solution at room temperature, and then rinsed 
thoroughly for 1 m in running deionized water.  Slides were incubated in staining 
solution 30 m at 37 °C in darkness then rinsed 2 m in running deionized water. 
Coverslips were mounted with Glycergel (DakoCytomation).  Images were obtained 
using a BX51 microscope fitted with DP-12 digital camera system (Olympus). 
 
Antibody-dependent enhancement assays.  Virus (1 - 2 × 104 p.f.u.) was 
incubated for 1 hr with affinity-purified IgG with or without added C′.  Macrophages 
were incubated with mixtures (m.o.i. = 0.1), or with medium, or virus only as controls.  
Samples were tested in triplicate and incubations were done at 37 oC in 5 % CO2.  
After 3 hr, media were aspirated from individual wells, and cells were washed three 
times with warm (37 oC) PBS to remove unbound virus and antibodies.  Fresh medium 
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 was added to each well and plates were incubated an additional 36 hr.  Supernatant 
and cells were harvested from each well for estimation of released and cell-associated 
viruses by plaque-assay.  Cells were lysed by three cycles of freeze-thawing to release 
cell-associated virus.  Plaque assays were performed by inoculating Vero cell 
monolayers with 200 µl of serially diluted supernatant or lysed cells.  After 1 hr, 
monolayers were overlaid with 1 % low melting point agarose, incubated for 3 d, 
stained, and plaques enumerated on day 4 as described above. 
 
Statistical analysis.  ELISA data from groups of infected and uninfected 
llamas were evaluated by analysis of variance.  Significance was assessed using 
Bonferroni’s and Tukey’s tests.  Values were considered statistically significant when 
p < 0.05. 
 
Results 
IgG isotypes induced during natural nematode infections  
 Recently we showed that only classical IgG1 antibodies could be detected in P. 
tenuis-llama serum using a worm-specific aspartyl protease inhibitor as capture 
antigens (14).  Although highly immunogenic, this antigen represented just one of the 
complex mix of worm proteins that the animals may become exposed to during 
infection.  As a result, heterogeneous soluble antigens prepared from infective third 
stage larvae (L3) was substituted in the ELISA to evaluate IgG isotypes that were 
induced by worm proteins.  As before, IgG1 dominated the response to L3 antigens in 
P. tenuis-infected llamas (n = 4); however, IgG2 HCAbs were also induced.  IgG3 
levels remained low (Fig. 3-1A).  IgG1 levels were significantly greater than IgG2 (p < 
0.05) and IgG3 (p < 0.01); however, the difference between IgG3 and IgG2 levels was 
not statistically significant.  As a comparison, we assessed sera from animals (n = 4) 
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Figure 3-1: Worm antigens induced IgG2 HCAbs and conventional IgG1 in llamas 
during natural infections. (A) IgG isotypes induced during P. tenuis infection in four 
animals. (B) Cross-reactive IgGs induced by heterologous worm infections in four 
animals.  Soluble P. tenuis L3 antigens (4 μg/ml) were used in ELISA to detect worm-
specific serum IgGs.  Symbols represent the mean optical density (OD; λ = 450) value 
for each isotype obtained from individual alpacas.  Horizontal bars represent mean OD 
values per group.   
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 that had been exposed to heterologous nematode infections.  Interestingly, these 
animals had also produced predominantly IgG1 and IgG2, but few IgG3 cross-reactive 
antibodies that bound P. tenuis L3 antigens (Fig. 3-1B).  These observations were 
congruent with the conclusion that IgG3 HCAbs were not efficiently induced by 
nematode infection. 
 
IgG isotypes induced during natural virus infection 
 To determine whether distinct isotypes were induced in response to virus, we 
assessed the IgG isotypes that were induced during natural infection with WNV.  Sera 
from alpacas (n = 4) that demonstrated serum-neutralization (SN) titers ranging from 
181 to 1448 (Table 3-1) were tested in ELISA using recombinant WNV envelope (E) 
and two non-structural (NS1 and NS5) proteins.  The IgG profile was similar for all 
the antigens tested in that, primarily IgG1 antibodies were detected; IgG2 and IgG3 
levels were equally low, except for one animal that had relatively high levels of anti-
NS1 IgG3 (Fig. 3-2A-C).  These samples were acquired during a serological 
surveillance program for WNV in camelids therefore, there were no clinical records 
available that documented the nature of their exposure to WNV.  Interpretation of the 
immune response data is confounded by the fact that the time of exposure is unknown. 
 
IgGs induced by WNV vaccine 
 We tested serum samples obtained from alpacas that had been administered 
three doses of a formalin-inactivated WNV vaccine under controlled, experimental 
conditions (15).  All the animals had measurable serum neutralization titers (Table 3-
1) and produced IgG antibodies specific for WNV E and NS1 proteins, but not NS5 
after two doses of vaccine (Fig. 3-3).  In contrast to the anti-nematode response, IgG3 
was induced together with IgG1 in response to vaccination.  With respect to the 
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Table 3-1:  Summary of the camelid serum neutralization titers obtained against West 
Nile virus 
Serum neutralization titer 
  days post-vaccination days post-infection
  21 44 63 155 365 393 ND
Vaccinated (group 1)    
Mr. Nitro N 512 2048 181  
Bottom Line N 724 1448 181  
Dancin Boots N 45 1024 91  
Crayola N 256 2048 128  
Conrad N 1024 4096 362  
Bull's eye N 362 1024 91  
Wild Thang N 1024 1024 91  
Novio N 181 1024 128  
Jag N 724 2048 128    
            
Vaccinated (group 2)    
#199   N  
#344   N  
#500   N  
#758   N  
#296   N  
#327   N  
#494   N  
#818       N    
            
Vaccinated/boosted    
#319   2896 
#723   2896 
#550   >4096 
#740        >4096  
            
Naturally infected    
Veronica    181
Colonel Fenwick    724
Macho Negro    1024
Prisa          1448  
ND, not determined; N, negative 
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Figure 3-2:  Conventional IgG1 dominates the IgG response to natural infection with 
West Nile virus.  WNV-specific IgG isotypes were detected in ELISA using envelope 
(E), and non-structural proteins (NS1 and NS5).  Bound IgGs were detected using 
peroxidase-conjugated goat anti-sera.  Horizontal bars represent mean OD values per 
group. 
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Figure 3-3: WNV vaccination induced IgG3 HCAbs and conventional IgG1 in 
alpacas. Alpacas (n = 8) were vaccinated three times (arrow heads) with killed, 
adjuvanted WNV. Antibodies specific for (A) WNV envelope (E), or (B and C) non-
structural proteins (NS1 and NS5) were detected by ELISA.  Mean OD450 values at 6, 
9 and 12 weeks post-vaccination were compared by ANOVA with values obtained at 
week 3 for each IgG isotype.  Significance (*, p < 0.05) was assessed using 
Bonferroni’s test.  Bars represent standard error of the mean.  Absence of antibodies to 
NS5 is compatible with the fact that the vaccine does not incorporate this protein. 
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 immunodominant E protein, IgG1 and IgG3 levels became significantly higher (p < 
0.05) than IgG2 by week six of the experiment (Fig. 3-3A).  The IgG response to NS1 
proteins was similar in kinetics but weaker than that for the E protein (Fig. 3-3B).  A 
weak IgG2 response to NS1 was detected.  As expected, there were no IgG responses 
induced against the NS5 protein as this is a virus-specific RNA polymerase, which 
was absent from the vaccine (Fig. 3-3C).  It took three vaccinations to elevate serum 
neutralization titers of alpacas to equal those of horses administered only two doses 
(15).  The data show that IgG2 is not efficiently induced by vaccination with killed 
virus. 
 
The anamnestic response in vaccinated alpacas 
 IgGs specific for WNV E protein were still detectable one year after 
vaccination (Fig. 3-4A); however, the anti-NS1 IgG response had diminished 
completely (Fig. 3-4B).  Administration of vaccine at this time elicited an anamnestic 
response, including IgG1 and IgG3 specific for the E and NS1 proteins.  These results 
document that all the isotypes are induced by re-vaccination.  In addition, a marked 
increase in IgG2 HCAb levels was detected against the E protein. 
The host cell receptor-binding domains of WNV are located within the E 
protein.  In other species, antibodies elicited against this protein have been reported to 
be highly effective at neutralizing virus.  We next sought to address whether the IgG 
isotypes induced against WNV could neutralize. 
 
Evaluation of virus-neutralizing activities of alpaca IgGs 
 To quantify neutralizing activities of WNV-induced antibodies, we compared 
the PRNT of sera from naturally infected with vaccinated/boosted alpacas.  Sera from 
vaccinated/boosted alpacas were 8-fold more potent in PRNT(90%) assays than sera 
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Figure 3-4:  Revaccination with WNV one year after primary immunization induced 
IgG3 HCAbs and IgG1 in alpacas.  (A and B) Anti-WNV E, but not anti-NS1, 
antibodies were detected in alpacas (n = 8) one year post-vaccination. Alpacas (n = 4) 
that were revaccinated at this time produced IgG2 along with increased concentrations 
of IgG1 and IgG3 against WNV E (C) and NS1 proteins (D). ELISA was conducted as 
described in Fig. 3-3.  Horizontal bars represent mean OD values per group. 
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 from naturally infected alpacas (Fig. 3-5).  To determine whether IgGs participated in 
neutralization, we purified IgG1, IgG2 and IgG3 from sera using affinity columns 
prepared with isotype-specific mAbs.  Antibodies were purified from sera of eight 
individual alpacas.  Homogeneity of each IgG preparation was confirmed by sandwich 
ELISA (data not shown).  Before assaying the purified IgGs in PRNT assays, we 
confirmed that they had not deteriorated during the purification process by testing 
them in ELISA using WNV E proteins.  Binding activities were preserved with one 
exception (Fig. 3-6).  The binding of IgG3 from naturally infected alpacas improved 
substantially after purification (Fig. 3-6A vs. Fig. 3-2).  One explanation for this 
change would be that IgG1 and IgG3 were induced against similar epitopes on WNV 
E protein, and once separated, IgG3 no longer had to compete for binding.  It is 
possible that, by virtue of its larger size IgG1 sterically hinders access of IgG3 to 
binding sites on the E protein.  Confident that the affinity-purified IgGs had retained 
their binding properties, we proceeded to test them in plaque-reduction assays. 
Neutralization assays were carried out by incubating WNV with two-fold 
dilutions of purified IgG1, IgG2 and IgG3, with or without C′, before inoculating Vero 
cell monolayers.  Conventional IgG1 and IgG3 HCAbs induced by either natural 
exposure or vaccination demonstrated potent neutralizing activities (Fig. 3-7).  
Neutralization was C'-independent at concentrations greater than 30 μg/ml for these 
isotypes from both groups of animals.  The role of C' was evident when IgGs produced 
by natural exposure were tested at concentrations lower than 30 μg/ml (Fig. 3-7A).  
IgG3 and IgG1 induced by hyper-immunization neutralized independently of C' even 
at 3 μg/ml (Fig. 3-7B).  Conversely, IgG2 induced in these animals demonstrated sub-
neutralizing activities (< 90% plaque-reduction), which were notably enhanced by the 
presence of C' (Fig. 3-7B).  In all the cases, WNV-induced IgG1 and IgG3 efficiently 
neutralized virus while IgG2 demonstrated sub-neutralizing properties. 
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Figure 3-5:  Detection of neutralizing antibodies in sera from naturally infected (A) 
and vaccinated alpacas (B). Standard PRNT were conducted with sera in the presence 
of C'. Sera were collected at onset of clinical signs from naturally exposed alpacas and 
one month post-boosting from vaccinated/boosted alpacas.  N = 4 alpacas per group. * 
indicates endpoint titer.  Dotted lines indicate positive threshold.  
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Figure 3-6:  Affinity-purification of IgGs did not impair epitope binding. IgGs 
affinity-purified from alpaca sera described in Fig. 3-5 were assayed for binding to 
WNV E protein in ELISA.  Horizontal bars represent mean OD values per group. 
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Figure 3-7:  IgG3 and IgG1 demonstrated comparable neutralizing activities for WNV 
while neutralization by IgG2 was inefficient. The PRNT assays were conducted with 
affinity-purified IgGs from naturally infected (A) and vaccinated (B) alpacas.  Filled 
symbols indicate values obtained with C′, open symbols, without C′.  Shaded areas 
represent concentrations at which IgGs where assessed for enhancement of WNV 
infection of alpaca macrophages (Fig. 3-9). 
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 Effect of IgG on WNV infection of macrophages 
 Antibody-dependent enhancement of viral infection is characteristic of 
flaviviruses.  In humans, dengue virus replicates primarily in Fc-receptor bearing 
monocytes and macrophages (18).  These cells are infected more efficiently in the 
presence of dengue virus-specific antibodies (19).  To assess the effect of anti-WNV 
IgGs on infectivity, we conducted experiments using macrophages prepared from 
alpaca peripheral blood.  
Cells were separated over density gradients to eliminate erythrocytes in alpaca 
blood that cannot be lysed using conventional methods (Fig 3-8A).  The cells obtained 
from the upper band were enriched in mononuclear cells (Fig. 3-8B), and the 
separation process was effective in eliminating polymorphonuclear cells (Fig. 3-8C).  
Within 8 days of culture, adherent monocytes had differentiated into macrophage-like 
cells that expressed cytoplasmic esterases specific for α-naphthyl acetate (Fig. 3-8D).  
Cells obtained from the polymorphonuclear cell layer of the density gradients did not 
react with α-naphthyl acetate (Fig. 3-8E). 
The ability of WNV to infect and replicate productively in alpaca macrophages 
was evaluated.  A multiplicity of infectivity (m.o.i.) of 0.1 established infection and 
resulted in considerable WNV replication; however, an m.o.i. = 10 proved too high 
resulting in a one step infection of all the cells, viral replication and subsequent cell 
death (Fig. 3-8F).  Titers of virus released within five days of established infections 
were low (20,000 p.f.u./ml), suggesting that alpaca macrophages are not highly 
permissive to WVN infection (Fig. 3-8F; left panel).  The results observed were not 
affected by inoculation time (Fig. 3-8F) or the addition of C′ (not shown). 
To assess the effects of WNV-specific IgGs on the early events of virus 
infectivity, WNV was incubated with IgG (10, 2, 0.4 and 0.08 µg/ml, and 50 µg/ml; n 
= 1), with or without added C′, prior to inoculating macrophages.   Cells (1 × 105)
 89
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Figure 3-8:  Purification and assessment of alpaca macrophages. 
(A) Density gradients (upper gradient - Histopaque 1077; lower gradient - Histopaque 
1119) were loaded with alpaca blood diluted 1:3 in PBS, and centrifuged 750 × g. 
(B, C)  Flow cytometric analysis of cell fractions isolated by density gradients.  
Scatter plots are shown for the low density (B) and high density (C) fractions.  Gates 
were set around red and dead cells (G1), lymphocytes (G2), monocytes (G3) and 
granulocytes (G4). 
(D, E) Cytospin preparations of adherent cells from low density fraction after 8 days 
in culture (D), or cells from the high density fraction (E).  Macrophages stained 
positive (black) for α-naphthyl acetate esterase but granulocytes did not. Scale bar 
represents 10 μm. 
(F)  Macrophages (1 × 105) were incubated for 1 hr (filled symbols) or 3 hr (open 
symbols) with WNV (m.o.i. = 10 or 0.1), rinsed with PBS and cultured at 37 oC for 5 
days.  Supernatant was collected at daily intervals and virus titrations were obtained 
by plaque assay.  Arrow indicates m.o.i. (0.1), inoculation period (3 hr) and time point 
of supernatant collection used in subsequent assays.  
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  were inoculated for 3 hr with 1 × 104 p.f.u. of WNV (m.o.i. = 0.1), and virus titers 
were obtained 36 hours after.  Enhancement of infectivity was observed with all three 
isotypes, but was variable among the preparations tested (Fig. 3-9).  Variability was 
apparent even among animals with similar isotype results on Vero cells.  In some 
instances virus replication was enhanced more than ten-fold by IgG1 and IgG3 
(animals V and 723).  In other cases, little or no enhancement was observed (Prisa and 
550) (Fig. 3-9).  Nevertheless, antibodies from seven of the eight animals showed 
enhancement with at least one isotype.  Inclusion of C′ reduced the enhancement 
effects in nearly all the preparations assayed.  Titrations of cell-associated viruses 
reflected those of released viruses but were considerably reduced (Fig.3-10). 
Overall, the data are compatible with the conclusion that WNV infection of 
camelid macrophages is limited; however, infectivity can be dramatically enhanced by 
low concentrations of WNV-specific IgG antibodies.  Enhancement process can be 
abolished in a C′-dependent manner. 
 
Discussion 
 The role of HCAbs in immunity is largely unknown.  This study is the first to 
document that IgG2 and IgG3 HCAbs have discrete roles in immune responses to 
nematode and viral infections.  In response to nematode infections, it is the IgG2 
heavy-chain isotype that is produced together with conventional antibodies.  
Conversely, viral infections induce IgG3 HCAbs that compete with conventional IgG1 
for epitopes on immunodominant E proteins.  In humans, Th1 cells produce INFγ that 
drives IgG1 and IgG3 production in response to infection with viral pathogens while 
parasitic nematode infections elicit a Th2 response.  This response is associated with 
the production of IL-4, IL-5, and IL-13, the induction of IgE and discrete IgG isotypes 
(IgG1 in mice and IgG4 in humans), basophilia, mastocytosis and eosinophilia.  
 91
  
 
 
 
 
 
 
 
 
 
 
Figure 3-9:  Antibody-dependent enhancement of WNV replication in alpaca 
macrophages. Virus was opsonized with IgGs purified from naturally infected (A) or 
vaccinated/boosted animal sera (B) prior to inoculating alpaca macrophages (Fig. 3-8). 
Supernatants were collected 24 hr post-inoculation and the titrations of virus released 
from infected cells were obtained by plaque assays. Filled symbols represent assay 
conducted with C′, open symbols, without C′.  Stippled lines represent virus obtained 
from macrophages inoculated with WNV only. 
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Figure 3-10:  Cell-associated virus titers were low but reflected titers calculated for 
virus released in the supernatant. Macrophages were infected with WNV as in Fig. 3-
9. Cell lysates were prepared by three cycles of freeze-thawing and virus titrations 
were obtained by plaque assays. Filled symbols represent assay conducted with C′, 
open symbols, without C′.  Stippled lines represent virus obtained from macrophages 
inoculated with WNV only.  In both groups n = 3. 
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 The Th1/Th2 paradigm has been characterised in the mouse and human, but does not 
appear to be enforced in other species, e.g. ruminants.  Disparities in the biophysical 
features of the unusual IgG2 and IgG3 produced by camelids predicted that these 
isotypes should display dissimilar effector functions.  Our data demonstrate that 
antigens that would normally generate Th1- and Th2-driven responses produced IgG2 
and IgG3 HCAbs, respectively, in infected camelids.  Clearly, synthesis of the two 
heavy-chain isotypes in camelids is influenced by distinct immune regulators.  
 A successful humoral immune response against virus infection is determined 
by the ability of the elicited antibodies to bind virus and neutralize infectivity.  West 
Nile virus is a member of the Flaviviridae family of viruses and is related to clinically 
important viruses such as those that cause dengue, yellow fever and Japanese 
encephalitis (20).  Its 11 kb RNA genome encodes a single polyprotein that is cleaved 
by both viral and host enzymes to yield three structural and seven non-structural 
proteins (21).   The E protein of WNV is comprised of three structural domains (I, II 
and III).  Domain III adopts an immunoglobulin-like structure and it is believed that 
receptor binding sites are located within this domain.  Antibodies raised against DIII 
are the most efficient at neutralizing WNV (22-24).  In our study, alpaca IgG3 HCAbs 
were induced against WNV E proteins and demonstrated inhibitory effects comparable 
to IgG1 when assayed for WNV neutralization using a fibroblast cell-line.  In addition 
to IgG1 and IgG3, hyperimmunization produced E-specific IgG2 HCAbs; however, 
this isotype failed to meet the threshold (PRNT90%) even when tested at 
concentrations exceeding 100 µg/ml.  Altogether, IgG3 HCAbs demonstrated effector 
properties that were consistent with virus neutralizing antibodies. 
Mononuclear cells are important sites of replication for flaviviruses.  Because 
these cells bear FcR, they phagocytose antibody-coated viruses and other particles, 
usually leading to destruction of the complex.  It has been reported that monoclonal 
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 antibodies that are highly efficient in neutralization assays using fibroblast cells can 
enhance infection of FcR-bearing cells by dengue virus (25).  To ascertain whether 
anti-WNV IgGs were able to neutralize virus infection of mononuclear cells, 
experiments were performed with macrophages prepared from alpaca blood.  We 
adapted a protocol for culturing bovine macrophages for this purpose.  The protocol 
that we developed worked quite well and we were able to culture monocytes that 
differentiated into large, vacuolated cells of dendritic morphology.  Within 8 days of 
culture, cells were confirmed to be macrophages using conventional cytologic 
methods.  The cells were used in infection assays at day 14 of culture.  When infected 
with WNV alone or in the presence of C′, viral replication in alpaca macrophages was 
low.  In other studies, equine monocytes/macrophages have been shown to be 
susceptible to WNV replication attaining titers of 3.2-6.6 log10 p.f.u./ml (26).  Here, 
we demonstrated that replication of WNV in alpaca macrophages is less efficient. 
Interestingly, IgG1 and IgG3 induced by natural infection enhanced WNV 
infectivity of alpaca macrophages.  However, in the presence of C′, enhancement was 
abolished.  In contrast, IgG1 and IgG3 induced by hyperimmunization also enhanced; 
however, C′ only reduced virus production and did not abolish it.  The starting IgG 
concentration (10 µg/ml) used in these experiments was selected because it was the 
concentration at which neutralization of WNV infectivity of Vero cells declined, and a 
dependency on C′ was evident.  At these diluted concentrations, antibodies enhanced 
infectivity in macrophages, but C′ abrogated this effect.  Thus, the neutralization data 
were correlated with the enhancement data. 
It has been established that IgG can mediate antibody-dependent enhancement 
(ADE) of  West Nile virus infection (27).  Although there are several mechanisms that 
have been suggested, the most widely accepted mechanism for ADE of viruses 
involves Fc-receptors (28).  Virus attachment to target cells is facilitated when Fc 
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 portions of antibodies complexed with viruses bind to FcγRs.  It has been shown that 
dengue virus replication mediated by FcR-dependent ADE can lead to suppression of 
anti-viral gene expression (29).  In our system, clearly WNV replication in 
macrophages is mediated by an ADE mechanism.  WNV-specific IgGs may serve as a 
bridge that strengthens the interaction of the virus with cells to bring about entry.  
Likewise, the virus may take advantage of the phagocytic pathway to avert detrimental 
cellular responses.  In other species, macrophages express FcγRI, FcγRII and FcγRIII 
on their surface.  In dengue virus infections, human FcγRI and FcγRII have been 
shown to mediate ADE in vitro (30).  FcγRs have not been described in camelid 
leukocytes; however, amino acid motifs are present within the camel IgG2 CH 
domains that are essential for binding of the human FcγRI.  Also, camelid IgG1 and 
IgG3 bind to protein G, an orthologue of FcγRIII.  It is likely that ADE of WNV in 
alpaca macrophages is mediated by an FcγR-dependent mechanism.  We intend to 
confirm the presence of FcγRs using flow cytometric methods. 
 Other mechanisms of ADE of viruses involve activation of C′ by the classical 
pathway (31).  In our system, C′ served to augment antibody neutralizing but not 
enhancing activities.  This observation concurs with similar reports documenting the 
protective effect of C′ activation during WNV infection in mice (32, 33).  The non-
structural glycoprotein, NS1, has also been shown to produce antibodies that 
neutralize WNV to prevent lethal infection in mice (34).  The antibodies assessed in 
our study were polyclonal in nature and showed reactivity with NS1 proteins in 
ELISA.  It is likely that anti-NS1 antibodies contribute to the neutralizing effects of 
camelid IgGs. 
 In aggregate, our data provide evidence supporting distinct immune functions 
for the IgG2 and IgG3 HCAbs.  IgG2 participates in anti-nematode responses while 
IgG3 are effective neutralizing antibodies that have relevance in anti-viral immune 
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 responses.  Both heavy-chain isotypes are induced by vaccination.  These findings 
enrich our understanding of camelid immunity, have implications for therapeutic and 
diagnostic approaches to infectious diseases in camelids, and provide a foundation for 
efforts to improve the health and well-being of llamas and alpacas. 
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Contributions of Conventional and Heavy-Chain IgGs to the Alpaca 
Immune System during Fetal, Neonatal and Adult Life3 
 
 
 
 
 
 
 
 
 
 
                                                 
3Lisa P. Daley, Stephen R. Purdy, William C. Davis, and Judith A. Appleton. Contributions of 
conventional and heavy-chain IgGs to the alpaca immune system during fetal, neonatal and adult life.  
Manuscript in preparation. 
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 Abstract 
 In addition to conventional immunoglobulins, camelids produce antibodies that 
do not incorporate light chains into their structures.  These so-called heavy-chain 
antibodies (HCAbs) have incited great interest in the biomedical community as they 
have considerable potential for biotechnological and therapeutic application.  
Comparatively little is known about their immunological functions and the B 
lymphocytes that produce them.  Focusing on the alpaca, we set out to clarify the life 
histories of B lymphocytes that synthesize heavy-chain or conventional IgGs and to 
determine the contribution of these isotypes to maternal immunity that is conferred on 
neonates via colostrum.  While conducting these studies, we were able to document 
the presence of a second conventional IgG isotype and showed that it is synthesized by 
cells that localize to the marginal zone of the spleen in adult alpacas.  In addition, we 
identified for the first time a third heavy-chain isotype, most closely related to the 
previously defined IgG3. Cells staining positive for this heavy-chain isotype were 
detected in adult, ileal Peyer’s patches, in contrast none of the other four isotypes were 
detected at this site.  All five isotypes were present in colostrum and were passively 
transferred to crias.  The concentrations of heavy-chain isotypes in cria blood declined 
more rapidly than conventional IgGs, suggesting that they have a shorter half-life.  
Our findings are compatible with specialized functions for IgG sub-isotypes in the 
alpaca. 
 
Introduction 
The camelids are the only mammals known to produce functional IgG isotypes 
that do not incorporate L-chains into their structures (1, 2).  The term heavy-chain 
antibody (HCAb) has been assigned to these unusual IgG isotypes.  There are three 
IgG isotypes reported to be produced by camelids: IgG1 is a conventional isotype, 
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 IgG2 and IgG3 are HCAb isotypes.  It must be emphasized that the nomenclature of 
camelid IgGs in no way correlates with that of the rodent or human isotypes.  In fact, 
at the time of discovery in dromedaries, these IgG isotypes were named according to 
decreasing apparent molecular masses of their H-chains as revealed by SDS-PAGE 
under reducing conditions, and subsequently by their differential binding to protein A 
and protein G (1, 3-5).  While all three isotypes will bind to protein A, protein G will 
only bind the conventional IgG1 and the IgG3 HCAb.  This difference has been 
exploited to separate the isotypes from serum in order to calculate concentrations; 
however, this method does not yield pure fractions. 
Distinct V and C genes encode HCAb and conventional IgGs.  In fact, 
approximately 42 germline genes encoding HCAb V domains (VHH) and 50 encoding 
conventional V domains (VH) have been reported for the dromedaries (6).  The 
hallmark of VHH genes is that they encode extended CDR3 loops as well as amino 
acid substitutions at five distinct positions within the framework two region (5, 7).  In 
addition, cDNA sequences point to the existence of at least six functional IGHG 
genes; IGHG1A and IGHG1B correspond to conventional IgG1a and IgG1b isotypes, 
IGHG2A, IGHG2B, IGHG2C putatively encode IgG2a, IgG2b and IgG2c, 
respectively, and a single IGHG3 correlates to IgG3 (3, 5, 8, 9).  Sequences for the 
IGHG2B gene has only been obtained in cloned genomic DNA from llamas and 
apparently is not produced by camels (3).  The IGHG genes encoding HCAbs have a 
distinguishing mutation within the splice consensus sequence of the CH1 that results 
in the exclusion of this domain from the protein structure (8).  All the IGHG genes 
encode IgGs with distinct hinge regions and as such these proteins have been 
classified into sub-isotypes (10).  Interestingly, the VHH and VH rearrange with the 
same set of J and D genes, which is suggestive of a clustered or interspersed 
arrangement (11).  In the dromedary, genomic and cDNA sequences have been 
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 obtained for a conventional IgM, and cross-reactive antiserum indicates the presence 
of IgA; however, at this time none of this evidence is available for llamas.  Neither is 
there any information on IgD and IgE isotypes produced by the camelids.  Of 
particular interest is the fact that an IgM HCAb remains elusive. 
The bio-physical attributes of HCAbs are consistent with those of conventional 
antibodies with some important exceptions.  The H-chains of HCAbs have lower 
apparent molecular masses than those of conventional IgG due to the absence of CH1 
domains.  Also, being devoid of L-chains, their unencumbered structures likely make 
HCAbs more tissue-diffusible and allow them to bind epitopes otherwise inaccessible 
to their conventional counterparts.  Like conventional Ig, HCAbs are bivalent 
antibodies; however, just a single VHH comprises the Ag-binding platform.  In fact, 
the extended CDR3 loops provide an increased Ag-binding surface to compensate for 
the loss of the VL, and coincidently, this loop contains many hypervariable regions 
that contribute to the high affinity of the HCAbs for antigens (12, 13).  The HCAbs 
undergo somatic hypermutation (1, 14), and remarkably, when induced against 
enzymes, these antibodies preferentially bind epitopes within clefts housing the 
catalytic sites (14-16).  The aggregate physical features of HCAbs, and the ease in 
which their VHH domains can be expressed in bacterial and yeast systems, make them 
attractive biotechnological and therapeutic tools (17-19). 
The HCAb isotypes constitute approximately 50 % of serum IgGs compatible 
with a significant role in camelid immunity (1). Studies of HCAbs remain primarily 
molecularly based.  Little research has been done to elucidate the immunological and 
physiological relevance of these antibody isotypes.  The exact concentrations of 
HCAb isotypes in body fluids are unknown.  The contribution of HCAbs to maternal 
antibodies to newborn health and well-being has not been investigated.  Information 
on the B lymphocytes that produce these unusual antibodies is lacking.  And, at this 
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 time, published reports investigating immune regulators of HCAb expression remain 
sparse.  These investigations have been hindered chiefly by the dearth of available 
isotype-specific reagents.  However, we have recently produced and fully 
characterized mAbs that bind specifically to the IgG isotypes produced by llamas and 
alpacas (20). 
This study describes the application of IgG isotype-specific mAbs in 
physiological assessments of camelid HCAbs and the B cells that produce them.  Here 
we report for the first time that Lama spp. produce not one, but two types of IgG3 
HCAb.  In addition, we now have the reagents to distinguish the two conventional 
IgG1 isotypes produced by llamas and alpacas.  The concentrations of lamoid IgG 
isotypes within body fluids have also been described, and lastly, the efficiency of these 
mAbs in immunohistochemical applications has allowed us to illustrate the 
distribution of HCAb+ and conventional B cells within different lymphoid tissues. 
 
Materials and Methods 
Reagents 
MAbs specific for llama/alpaca IgG1 (24F1, 26G11, 27E10, and 28G4), IgG2 
(10E6, 13A9, 16A4, 16H10 and 19D8) and IgG3 (1C11, 1D1, 2B11, 3E6 and 8E1) 
have been described elsewhere (20).  LH41A and LT97A bind undetermined cell 
surface epitopes expressed by llama/alpaca B and T lymphocytes, respectively 
(Washington State University Monoclonal Antibody Center) (21).  TH14B binds 
MHC II expressed by llama/alpaca cells (WSU Monoclonal Antibody Center).  Horse-
radish peroxidase (HRP)-goat antibodies to llama IgG (H + L) (Bethyl) were used in 
ELISA and Western blots.  Mouse antibodies were detected using HRP-goat anti-
mouse IgG (Cappel).  HRP-streptavidin was used in immunohistochemistry (SAv, 10 
µg/ml; Pierce Biotechnology Inc.).  Phycoerythrin (PE) anti-mouse IgM (clone II/41, 
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 0.6 µg/ml; eBioscience), SAv-peridin chlorophyll-a protein (PerCP, 0.6 µg/ml; BD 
Pharmingen), and fluorescein (FITC)-goat anti-camelid IgM (5 μg/ml; Triple J Farms) 
were used in flow cytometry. 
 
SDS-PAGE and Western blots 
IgGs were resolved in discontinuous, 15 cm polyacrylamide gels under 
reducing and non-reducing conditions as described elsewhere (20).  Samples and 
molecular weight markers (Bio-Rad Laboratories) were boiled 7 minutes in sample 
preparation buffer, with or without 2-mercaptoethanol, before loading.  Gels were 
either stained 1 hr with Coomassie blue or transferred to nitrocellulose membranes. 
Western blots were developed at room temperature. Each incubation step was 
conducted for 1 hr unless specified otherwise. Membranes were blocked with 5% skim 
milk in Tris-buffered saline (TBS) and washed with TBS containing 0.05% Tween 20 
and 0.1% bovine serum albumin (BSA; Sigma).  HRP-conjugated goat anti-llama IgG 
(H+L) was diluted in blocking solution containing 10% normal goat serum.  Antibody 
binding was detected with a chemiluminescent substrate (ECL reagent, Amersham 
Pharmacia Biotech, Piscataway, New Jersey) and autoradiography.  Films were 
scanned and images were prepared using Adobe® Photoshop® and Microsoft® 
Powerpoint®. 
 
Affinity purification of alpaca IgGs 
IgG isotypes were purified by affinity chromatography (20).  Columns were 
prepared by coupling 10 mg antibodies (26G11, 27E10, 19D8, 1D1 or 8E1) to 1 g 
CNBr-activated Sepharose-4B (Sigma) in the presence of 0.1 M NaHCO3, pH 8.0.  
Unbound active sites were blocked with 0.1 M Tris, pH 8.0 for 2 hrs at 4 oC.  The 
coupled gels were washed alternately with 0.1 M acetate buffer, pH 4.0 and borate 
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 buffered saline (BBS), pH 8.5. Alpaca sera or colostrum were diluted 1:5 in BBS 
before loading columns.  Samples were always loaded onto the 8E1 column before 
loading onto the 1D1 column.  Unbound proteins were washed from columns using 
BBS. Bound IgGs were eluted with 0.1M glycine-HCl buffer, pH 2.7, into tubes 
containing 0.1 M Tris-HCl, pH 9.0, and characterized by Western blot. 
 
Identification of IgG isotypes contained in protein G eluate 
Fourteen mAbs that were generated against llama IgG1, IgG2 or IgG3 were 
employed in ELISA to identify the isotypes that bound protein G.  Individual 96-well 
microtiter plates (Costar) were coated with 1 μg/ml of the protein G eluate containing 
unknown IgG isotypes, or affinity-purified llama IgG1, IgG2 or IgG3 diluted in 10% 
DPBS and incubated overnight at 4 oC.  The working volume was 25 μl/ml unless 
stated otherwise. Subsequent incubations were conducted at room temperature and 
wells were washed with 0.05% Tween 20, DPBS after each step.  Wells were blocked 
with 50 μl of 2% skim milk, 0.05% Tween 20, DPBS then incubated with hybridoma 
supernatant diluted 1:10 in blocking solution.  Bound mAbs were detected with 5 
μg/ml HRP-goat anti-mouse IgG diluted in 10% normal goat serum, blocking buffer.  
The assay was developed with 3,3,5,5'-tetramethyl-benzidine (TMB, KHL) and 
reactions were terminated with 1M H3PO4.  Optical density (O.D.) readings were 
obtained at 450 nm wavelengths.  
 
Collection of alpaca blood and lacteal fluids 
Samples collected from fourteen healthy alpaca dam-cria pairs (Cas-Cas-Nac 
farm, Perkinsville, Vermont) were evaluated.  Lacteal secretions were collected at 
parturition (colostrum) and 24 hrs later (transitional milk).  Blood samples were  
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 collected from dams and crias by jugular venipuncture in Becton-Dickinson 
vacutainers, centrifuged to separate sera, and sera were stored at -20 oC until use. 
 
Calculation of IgG concentrations 
The ELISA described above was modified to calculate IgG concentrations in 
lacteal fluids and sera.  Fluids were assayed directly for all isotypes except for 
IgG31D1.  In that instance, samples (n = 3) were depleted of IgG38E1 over 8E1-
sepharose affinity columns then reconstituted to original volume prior to use in 
ELISA. 
Microtiter plates were coated with 5 μg/ml mAbs in 10% DPBS and incubated 
overnight at 4 oC.  Wells were blocked with 2% skim milk, 0.05% Tween 20, DPBS 
then incubated with serial dilutions of sera or lacteal secretions.  Affinity-purified 
IgGs were used as standards.  Bound alpaca antibodies were detected with 0.1 μg/ml 
HRP-goat anti-llama IgG diluted in 10% normal goat serum, blocking buffer.  The 
assay was developed with TMB, terminated with 1M H3PO4, and O.D. values were 
obtained at 450 nm wavelengths.  The O.D. values of the standards were plotted 
against respective IgG concentrations, and the line equation was used to extrapolate 
the IgG concentrations of the samples tested. 
 
Immunohistochemistry 
Lymphoid tissues were collected from animals submitted to the Cornell 
University Hospital for Animals necropsy service.  Tissues were collected from two 
fetuses (5 and 6 months of gestation) and seven adult male and female animals (2 – 14 
years of age).  Tissues were embedded in tissue freezing medium (Electron 
Microscopy Sciences, Ft. Washington, Pa.) and snap-frozen on dry ice.  Sections (7 
µm) were prepared (Cryocut 1800; Reichert-Jung, Buffalo, N.Y.), mounted on glass 
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 slides, and stored at –80 °C. Slides were warmed to room temperature then fixed in 
100% acetone for 10 m.  Endogenous peroxidase activity was blocked with phosphate-
buffered saline (PBS) containing 0.3% H2O2 and 1% NaN3.  As a general blocking 
step, sections were incubated in PBS containing 5% skim milk and 10% NGS.  
Subsequent procedures were conducted at room temperature and slides were washed 
in three changes of PBS following each incubation step.  Sections were incubated with 
mAbs diluted in the general blocking solution.  Bound antibodies were detected with 
HRP-conjugated goat anti-mouse IgG and color development was carried out using 3-
amino-9-ethylcarbazole (AEC; Sigma).   Sections were counterstained with Gill's no. 
2 hematoxylin (Vector Labs), rinsed in tap water, mounted with Glycergel (DAKO 
Corp., Carpinteria, Calif.), and photographed images were obtained using a BX51 
microscope fitted with a MagnaFIRE SP digital camera system (Olympus, Melville, 
N.Y.). 
 
Flow cytometric analysis 
Blood or single cell suspensions (prepared by mechanically disrupting tissues) 
were layered onto density gradients (upper gradient - Histopaque® 1077; lower 
gradient - Histopaque® 1119; Sigma) in polypropylene tubes.  Tubes were centrifuged 
with brake off in a swinging bucket rotor at 700 × g for 1 hr at 26 oC.  Supernatant was 
aspirated within 0.5 cm of the mononuclear cell layers (at the plasma-upper gradient 
interface) and discarded.  Mononuclear cells were transferred to fresh 15 ml 
polypropylene tubes and washed three times with PBS for 10 m at 250 × g. 
Cells were stained for flow cytometric analysis as described by Davis et. al 
(21).  Briefly, cells were treated with 10% normal mouse serum in PBS for 20 m on 
ice, stained with fluorescent antibodies for 1 hr at room temperature, washed with 
PBS, and analyzed with a FACSCaliber flow cytometer (Becton Dickenson, 
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 Mansfield, Mass.).  For data acquisition, 104 events were collected within a gate 
encompassing lymphocytes. Phenotypic analysis was performed using CellQuest 
Software (BD Pharmingen). 
 
Results 
Discovery of a new HCAb and isolation of two IgG1 proteins produced by 
alpacas 
 For other studies, affinity-columns were prepared and used to deplete serum of 
IgG antibodies.  Despite confirming that individual IgG isotypes had been completely 
removed from serum (by eventually obtaining no peaks during the elution steps), a 
substantial amount of protein was obtained when the unbound fraction was loaded 
onto a protein G column.  This protein G eluate was resolved by SDS-PAGE under 
reducing conditions and found to contain four distinct protein bands; three of which 
were detected in Western blot by polyclonal antibodies to llama IgG (H+L) (Fig. 4-
1A).  A fourth weak band having the slowest electrophoretic mobility was not detected 
by the anti-IgG antibodies.  This protein band migrated just above the 66.2 kDa 
molecular mass marker under both reducing and non-reducing conditions, which was 
identical to the electrophoretic mobility of albumin in alpaca serum resolved under 
these conditions (data not shown). 
To ascertain which IgG isotypes remained in the protein G eluate, an ELISA 
was conducted using a panel of 14 isotype-specific mAbs (20).  Four mAbs reacted 
with epitopes within the protein G eluate; three that were raised against llama IgG1 
(24F1, 26G11 and 28G4) and one that was raised against llama IgG3 (1D1) (Fig. 4-
1B).  The 26G11 (that was monospecific for epitopes within the protein G eluate) and 
1D1 mAbs were subsequently used to prepare affinity columns, and together with 
27E10, 19D8 and 8E1 columns, were used to separate IgGs from alpaca serum. 
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Figure 4-1:  Identification of novel IgGs in alpaca serum.  Affinity columns were 
prepared by coupling anti-IgG1 (27E10), IgG2 (19D8) or IgG3 (8E1) mAbs to 
Sepharose.  Serum was passed over all three columns before loading onto a protein G 
column. (A) Protein G eluate was resolved by SDS- PAGE under reducing conditions.  
Gels were stained with Coomassie blue (Cb) or blotted onto nitrocellulose membranes 
for development with HRP-goat anti-llama IgG (H+L) (WB). Hc; heavy chain; Lc; 
light chain. (B) Protein G eluate was analyzed in ELISA with a panel of mAbs specific 
for llama IgG isotypes (30). Plates were coated with 1 µg/ml of the unknown protein 
or affinity-purified IgG1, IgG2 or IgG3.  Supernatants from 14 hybridoma clones were 
applied to the wells at 1/10 dilution.   Bound mAbs were detected using HRP-goat 
anti-mouse antibodies.  Arrows indicate mAbs that were selected for use in subsequent 
assays. Asterisks denote binding by anti-IgG1 (27E10), IgG2 (19D8) or IgG3 (8E1) 
mAbs that were used to prepare affinity columns.   
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 The eluates from all five affinity-columns were characterized by SDS-PAGE 
(Fig. 4-2A and B) and detected by polyclonal anti-llama IgG antibodies in Western 
blot (Fig. 4-2C and D).  Apparent molecular masses were calculated for each of the 
proteins resolved under reducing conditions (Table 4-1).  Eluates from the 27E10, 
19D8 and 8E1 columns resolved similarly to previously published results (20).  The 
26G11 column bound one conventional IgG, with H-chains (49.9 kDa) that resolved 
separately from L-chains (23.1 to 25.5 kDa) under reducing conditions (Fig. 4-2, A 
and C).  Interestingly, the L-chains of IgG126G11 went undetected by the polyclonal 
goat anti-llama (H+L) (Fig. 4-2C). When the disulfide bridges were intact, this 
26G11-bound IgG had a retarded electrophoretic mobility compared with the 27E10-
specific IgG1 (Fig. 4-2, B and D).  It has been established that two IgG1 sub-isotypes 
are produced by camelids based on DNA analyses (5), so it was not surprising that we 
could isolate an additional isotype from alpaca serum.  Hereafter, these isotypes will 
be distinguished as IgG127E10 (50.9 kDa) and IgG126G11 (49.9 kDa) (Table 4-1) as 
amino acid sequences have to be obtained to tether these proteins to published IgG1a 
and IgG1b gene sequences (5). 
Surprisingly, the IgG eluted from the1D1 column resolved in a manner similar 
to IgG38E1 as a single HCAb species under reducing conditions (Fig. 4-2, A and C).  
Because this HCAb was bound by protein G and detected by commercial polyclonal 
antisera against llama IgG as well as our anti-IgG3 mAb, we have assigned it to the 
IgG3 isotype.  We report for the first time that a second type of IgG3 with an apparent 
molecular mass of 44.3 kDa is produced by alpacas, which will be referred to as 
IgG31D1 (Table 4-1). 
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Figure 4-2:  Six IgG isotypes were isolated from alpaca serum.  Affinity columns 
were prepared by coupling anti-IgG isotype mAbs to Sepharose.  Serum was loaded 
onto these columns and bound proteins were eluted and characterized by SDS-PAGE 
under reducing (A and C) and non-reducing conditions (B and D).  Gels were stained 
with Coomassie blue (A and B) or blotted onto nitrocellulose membranes for 
development using HRP goat anti-llama IgG (H+L) (C and D). Arrows highlight 
lanes containing novel IgG proteins isolated from alpaca serum.  
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Table 4-1:  Apparent molecular masses of IgG proteins purified from alpaca serum 
Isotype Specific mAb
Hc Lc
IgG1 27E10 50.9 27.0 - 24.0
26G11 49.9 25.5 - 23.1
IgG2 19D8 43.4
40.5
IgG3 1D1 44.3
8E1 43.4
Molecular mass (kDa)
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 Concentrations of IgG isotypes in lacteal secretions and serum 
In addition to the three mAbs we previously described as being specific for 
llama IgG1, IgG2 and IgG3 (20), we have discovered two additional mAbs that 
recognized a novel IgG3 HCAb as well as a second conventional IgG1 in alpaca 
serum.  These five mAbs were subsequently employed in assays to describe the 
distribution of IgG isotypes in alpaca body fluids. 
IgG is the predominant isotype in both camelid and ruminant colostrum.  We 
set out to investigate the contribution of HCAbs in alpaca lacteal secretions.  Capture 
ELISAs were conducted to compute IgG concentrations in colostrum, transitional milk 
and serum (19).  In the case of colostrum, because 1D1 reacted with both IgG3, 
samples (n = 3) were depleted of IgG38E1 prior to use in ELISA to calculate IgG31D1 
concentrations. 
All of the IgG isotypes were present in alpaca colostrum (Fig. 4-3A).  
Combined, the HCAbs represented 38.5% of the total colostral IgG.  The predominant 
isotype in colostrum was the conventional IgG127E10 (43 %) with a mean concentration 
of 84.4 mg/ml (+ 14.11 SE; n = 14), ranging between 18.3 - 176.8 mg/ml.  The mean 
IgG127E10 concentration was significantly greater than the mean concentration of all 
the other IgG isotypes (p < 0.001) (Fig. 4-3A).  The conventional IgG126G11 and the 
IgG3 HCAbs were equally represented in colostrum; IgG126G11, 18.5 % (n = 14), 
IgG38E1, 16.3 % (n = 14) and IgG31D1, 13.6 % (n = 3).  The mean concentration of 
IgG126G11 was 36.3 mg/ml (+ 6.4 SE; ranging from 6.7 - 74.5 mg/ml).  IgG38E1 had a 
mean concentration of 31.9 mg/ml (+ 5.7 SE; ranging from 2.2 to 68.0 mg/ml) while 
IgG31D1 was 26.7 mg/ml (+ 7.3 SE; ranging from 14.1 – 39.4 mg/ml).  The IgG2 
HCAbs were the least represented (8.6 %; n = 14) in colostrum, with a mean 
concentration of 16.9 mg/ml (+ 3.17 SE; ranging from 3.6 – 42.7 mg/ml).  In total, 
colostrum had a mean IgG concentration of 196.2 mg/ml (+ 25.9 SE, n = 14) ranging  
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Figure 4-3:  Distribution of IgG isotypes in lacteal secretions and serum of alpaca 
dams.  IgG concentrations were measures in ELISA using affinity-purified IgGs as 
standards.  As the 1D1 mAb bound both IgG3 isotypes, the samples were depleted of 
IgG38E1 prior to assay by 1D1 in ELISA.  IgG concentrations are reported for (A) 
colostrum, (B) milk, and (D) serum.  (C) Total IgG concentrations were calculated by 
tallying the values for each isotype. Mean IgG concentrations were compared by 
ANOVA and significant differences (*, p < 0.5; **, p < 0.01; ***, p < 0.001were 
assessed using Tukey’s test.  In all groups, n = 14, except for 1D1 values where n = 3.  
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 from 44.9 – 401.4 mg/ml.  Overall, all the IgG isotypes present in serum are 
consistently represented in alpaca colostrum.  This is in contrast to the ruminants 
where colostrum contains predominantly one IgG isotype. 
Colostrum is highly enriched with antibodies; however, these antibodies 
decline significantly in concentration over time.  We found that, coincidental with ~ 
90 % decrease in total IgG concentrations (Fig. 4-3C), all the isotypes decrease 
accordingly in dams’ milk 24 hr post-parturition (Fig. 4-3B).  That is, the mean 
concentration of IgG declined to 17.3 mg/ml (+ 3.1 SE; n=14) within 24 hr post-
parturition, which was equivalent to IgG levels in serum (Fig. 4-3D).  Again, the mean 
concentration of IgG127E10 (7.6 mg/ml + 1.6 mg/ml SE) was significantly higher (p < 
0.001) than IgG126G11 (2.9 mg/ml + 0.6 mg/ml SE), IgG2 (1.4 mg/ml + 0.3 mg/ml SE) 
and IgG38E1 (2.9 mg/ml + 1.0 mg/ml SE).  The mean concentration of the novel 
IgG31D1 was 2.5 mg/ml + 0.9 mg/ml SE; n = 3).  IgG126G11 and the IgG3 HCAbs were 
equally represented in 24 hr milk while IgG2 was the least represented. 
To evaluate whether IgG distributions in lacteal fluids reflected those in sera, 
the concentrations of IgG isotypes present in dams’ sera at 24 hr post parturition were 
calculated.  The mean concentration of total IgGs in serum was (18.8 + 1.5 mg/ml SE; 
n=14).  IgG127E10 was the predominant isotype present in serum (n = 14) (Fig. 4-3D).  
The mean concentration of IgG127E10 (6.9 mg/ml + 0.7 mg/ml SE) was significantly 
greater than IgG126G11 (p < 0.01; 4.3 mg/ml + 0.7 mg/ml SE) as well as the IgG2 and 
IgG38E1 HCAbs (p < 0.001; 1.2 mg/ml + 0.3 mg/ml SE and 2.2 mg/ml + 0.5 mg/ml 
SE).  However, in contrast to lacteal fluids, the mean IgG126G11 concentration was 
significantly greater than IgG38E1 (p < 0.05) as well as IgG2 HCAbs (p < 0.001). The 
mean concentration of the novel IgG31D1 was 4.2 mg/ml + 1.5 mg/ml SE; n = 3).  
Collectively, the data demonstrate that all the IgG isotypes present in serum, including 
the HCAbs, were proportionately transferred to lacteal fluids. 
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 Half-life (t1/2) of maternal IgGs in cria serum 
We assessed the kinetics of IgG concentrations in sera from newborn crias 
from 24 hr post-partum to 3 m of age.  As previously described (23-26), maximum 
concentrations of maternal IgG were obtained at 24 hr post-partum in cria sera 
(22.2mg/ml + 4.8 mg/ml SE, n = 14) (Fig. 4-4).  There were no correlations between 
individual IgG concentrations in colostrum and that in cria serum at 24 hr post-partum.  
An r2 = 0.49 value was observed between total IgG concentrations in colostrum and 
cria serum; however, this was not statistically significant.  Maternal HCAbs declined 
much more rapidly than conventional IgG1 in cria serum as concentrations fell by 50 
% within 14 d as opposed to 25 d and 20 d for IgG127E10 and IgG126G11, respectively 
(Table 4-2).  The half-life of maternal IgG31D1 in cria sera was not calculated.  In 
contrast to the other isotypes, a notable increase in the IgG127E10 and IgG38E1 
concentrations were observed in cria sera after 42 d of birth (Fig. 4-4 A and D), 
indicating that cria B cells had begun to secrete measurable quantities of antibodies. 
 
Distribution of B cells within adult lymphoid tissues 
In order to describe the distribution of HCAb-producing cells, we examined 
tissues from adult (n = 7) secondary lymphoid organs using flow cytometric and 
immunohistochemical methods.  Only the 27E10, 19D8 and 8E1 mAbs were used in 
flow cytometry as we had not discovered the second IgG1 and IgG3 antibodies at the 
time these experiments were conducted.  The data shown were results from one animal 
and are representative of results obtained with tissues from all seven. 
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Figure 4-4:  IgG concentrations in neonatal cria sera.  Concentrations of IgG1 (A and 
B), IgG2 (C) and IgG3 (D) were obtained by ELISA as described in Fig. 4-3. In all 
groups, n = 14, except for 1D1 values where n = 3.   
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Table 4-2:  Half-life (t1/2) of maternal IgG isotypes in neonatal sera. 
Isotype 
 
Specific 
mAb 
Mean conc. 
(mg/ml) 
 Day 1 of birth 
t1/2 
 
IgG1 27E10 6.34 25 
 26G11 3.18 
   
IgG2 19D8 1.12 
   
IgG3 8E1 1.46 
 1D1 5.88 ND
20 
 
14 
 
14 
  
In all groups n=14, except for 1D1 values where n = 3 
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 Twenty nine percent of cells in liver stained positive for B cell receptors (Fig. 
4-5).  IgM+ B cells predominated while IgG127E10+ and IgG38E1+ cells were present in 
equivalent numbers.  IgG2+ B cells were the least represented.  Few B cells for any 
isotype were identified by immunohistochemical staining, a result that was consistent 
with the flow data (data not shown). 
The LH41 mAb detected B cells within bone marrow, which were identified as 
conventional (IgM+ and IgG127E10+) and HCAb+ B cells (Fig. 4-6).  There were twice 
as many B cells expressing IgG127E10 (8.9%) compared to IgG2+ and IgG38E1+ cells 
(4.1%).  Combined, the percentage of IgG+ cells (17.2%) was greater than IgM+ cells 
(14.6%) (Fig. 4-5).  Thus, both conventional and HCAb-producing plasma cells 
resided within bone marrow. 
B cells were found dispersed along with T lymphocytes and MHC II+ 
throughout the lamina propria of the ileum (Fig. 4-7).  These B cells expressed IgM 
and all isotypes of IgG.  The B cells present in ileal Peyer’s patches stained positive 
only with the 1D1 mAb (Fig. 4-7; bottom row, center panel).  In flow cytometric 
analyses, IgG127E10+B cells were more prevalent than IgG2+ and IgG38E1+ B cells (16.3 
% vs. 4.2%, respectively) (Fig. 4-5).   
Flow cytometric analyses demonstrated that B cells within the spleen and 
mesenteric lymph nodes were predominantly IgM+ (Fig. 4-5).  IgG127E10+ and IgG38E1+ 
cells were equally represented while IgG2+ cells were rare.  In spleen, B cells were 
dispersed primarily within the red pulp compartment along with MHC II+ cells.  
Follicular B cells (LH41+) were shown to be confined to the marginal zones (Fig. 4-8; 
top row, left panel).  B cells present in red pulp were predominantly IgM+ while 
follicular B cells expressed all the IgG isotypes except IgG2.  Remarkably, marginal 
zone B cells expressed exclusively the IgG126G11 isotype (Fig. 4-8; middle row, right 
panel).   
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Figure 4-5:  Distribution of B cells within the different lymphoid compartments.  
Single cell suspensions were prepared from different alpaca tissues.  Cells were 
incubated with fluorochrome-conjugated antibodies and characterized by FACS 
analysis. Data are from one animal representative of n = 3.  mln; mesenteric lymph 
node  
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Figure 4-6:  All IgG isotypes are detected in plasma cells resident in bone marrow. 
Immunohistochemical staining for different B cell antigens was performed as 
described in Methods.  Positive cells are red. Scale bar = 50 μm.  
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Figure 4-7  Distribution of B cells in ileal lamina propia and Peyer’s patches.  
Immunohistochemical staining for surface markers and IgGs was performed as 
described in Methods.  M; muscularis. Broken line delineates Peyer’s patches (PP). 
Positive cells are red. Scale bar = 50 μm. 
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Figure 4-8:  Distribution of B cells in the adult spleen.  Immunohistochemical staining 
was performed as described in Methods.  F: follicle; RP: red pulp; MZ: marginal 
zone, A: arteriole; PALS: periarteriolar lymphoid sheath. Positive cells are red. There 
were no follicular B cells except for IgG31D1+ cells (arrow heads).  Scale bar = 50 μm.  
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 As expected, T cells were located within periarteriolar lymphoid sheaths (Fig. 4-8; top 
row, middle panel).  Within the mesenteric lymph nodes, IgM+ cells were present 
mainly within extrafollicular compartments and appeared to be excluded from 
germinal centers (Fig. 4-9; top row, left panel).  HCAb+ cells were present within 
germinal centers of lymph nodes; however, similar to IgM+ cells, IgG38E1+ B cells 
were observed mostly within extra-follicular areas (Fig. 4-9; bottom row, right panel). 
Overall, HCAb+ cells were distributed in conventional B cell compartments 
juxtaposed to T cells suggesting that these cells are poised to execute characteristic B 
cell functions.  However, IgG38E1+ B cells in mesenteric lymph node were found in 
extrafollicular regions while only IgG31D1+ cells were found in Peyer’s patches.  
Marginal zone B cells expressed IgG326G11.   
 
Development of B cells in fetal tissues 
To further describe the life history of B cells, we examined lymphoid tissues 
from alpaca fetuses at 5 and 6 m of gestation using immunohistochemical methods.  
Images from the 6 month-old fetus are shown; however, results were similar at both 
gestation periods.   
LH41+ B cells were detected in fetal liver; however, these cells were rare and 
found mainly within endothelial walls or in close proximity to hepatic blood vessels 
(Fig. 4-10A).  LH41+ B cells were more prevalent in the fetal bone marrow compared 
to the liver (Fig. 4-10B).  Follicles were observed within the ileum at mid-gestation 
and were found to contain LH41+ B cells (Fig. 4-10C).   None of the B cells present in 
6 m fetal liver, bone marrow and ileum stained positive for IgM or IgG antibodies.  T 
cells were detected within the thymus at this gestation period (Fig. 4-10D).
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Figure 4-9:  Distribution of germinal centers B cells in the mesenteric lymph node. 
Immunohistochemical staining was performed as described in Methods. Stippled lines 
delineate follicle and germinal center (GC). Positive cells are red. Scale bar = 50 μm.  
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Figure 4-10:  B and T lymphocytes were detected in fetal tissues at mid-gestation (6 
months). Immunohistochemistry was conducted on (A) fetal liver, (B) bone marrow, 
(C) ileal, and (D) thymic tissues collected as described in Methods. Tissue sections 
were incubated with LH41 that identifies B cells (A,B,C) or LT97 (D) that binds T 
cells. Positive cells are red.  Scale bar = 50 μm. 
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 The architecture of fetal spleen was fully developed at mid-gestation as the 
white pulp follicles were very distinct.  This organ was the most active site for 
lymphocytes of all tissues examined.  The LT97 mAbs identified T cells within 
periarteriolar lymphoid sheaths contiguous with B cell aggregates that stained positive 
with LH41 (Figs. 11; top row, left and centre panels).  MHC II+ APC formed 
aggregates between the PALS and adjacent blood vessels (Figs. 11; top row, right 
panel).  Follicular B cells expressed predominantly IgM and IgG127E10 (Figs. 11; 
middle row, left and centre panels); however, HCAbs were also being expressed at this 
stage of gestation (Figs. 11; bottom row).  All the reagents identified positive cells in 
extra-follicular regions of the spleen.  In the lymph nodes, B cells expressing both 
conventional IgG1 isotypes were located within the follicles (Figs. 12; middle row); 
however, HCAb+ B cells expressed predominantly the IgG38E1 isotype (Figs. 12; 
bottom row, right panel). 
Our observations are compatible with the conclusion that at mid-gestation, B 
cell lymphopoeisis occurs in fetal bone marrow, and that the spleen functions as the 
primary organ within which development occurs for both conventional and HCAb+ B 
cells. 
 
Discussion 
 
 Other than Tylopods, Camelus and Lama spp., only primitive chondrichthyan 
fishes are known to produce functional Ig lacking L-chains (27-29).  The camelid 
HCAbs emerged as a result of duplication of the conventional genes while the 
emergence and evolution of chondrichthyan HCAbs occurred independently of 
antecedent genes (11).  In camelids, HCAbs constitute as much as 45 – 75 % of IgGs 
in serum, yet very little is known about their immunological significance.  
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Figure 4-11:  Distribution of cells in fetal spleen.  Immunohistochemical staining was 
conducted as described in Methods. Stippled lines delineate white pulp including 
follicle. RP: red pulp; PALS: periarteriolar lymphoid sheath; B: B cell zone; A: 
arteriole. Positive cells are red.  Scale bar = 50 μm.  
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Figure 4-12:  Distribution of B cells in fetal lymph node. Immunohistochemical 
staining was conducted as described in Methods. Stippled lines delineate follicles.  
Positive cells are red. Scale bar = 50 μm.  
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 We have produced and characterized mAbs generated against llama IgGs that cross-
react with identical alpaca isotypes, which have allowed us to investigate just how 
these antibodies contribute to camelid immunity.  We report the discovery of a novel 
IgG3 that brings the total of HCAbs produced by Lama spp. to six.  Using the isotype-
specific mAbs that we generated against llama IgGs, it is now possible to investigate 
the immunological significance of HCAbs in camelid immunity and compare them 
with the functions of the conventional IgG1 sub-isotypes.  Presently, our reagents 
allow us to distinguish the two types of IgG1 and IgG3, but not the different types of 
IgG2.  The remaining anti-IgG2 mAbs will need to be characterized further to see if 
any of them are discriminating. 
 Whereas the concentrations of soluble IgG127E10 antibodies predominated in 
serum, IgG26G11 concentrations were comparable to both IgG3 antibodies while IgG2 
concentrations were consistently low.  In colostrum, the composition of IgGs reflected 
that of a more concentrated serum, and indeed all the isotypes were similarly 
represented.  It is established that, like ruminants, colostral IgG is crucial to the 
survival of neonatal crias.  Camelids are born severely hypogammaglobulinemic as the 
thick epitheliochordial placenta obstructs passive transfer of antibodies in utero and 
crias rely on maternal IgGs from colostrum (30, 31).  Failure of passive transfer of 
immunity by this route correlates well with morbidity and mortality in camelids (24, 
30).  While others have focused on the relevance of total IgG uptake in the crias, our 
study examined the contributions of individual IgG isotypes to the passive transfer of 
immunity from dam to cria.  Here, we confirm for the first time that, in contrast to 
ruminants, where the role of colostral IgG2 appears inconsequential as its level is < 6 
% that of IgG1 (32), all isotypes are represented in colostrum as they are in serum in 
alpacas. 
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 Our calculations of total IgG concentrations in dam colostrum (196.2 mg/ml + 
25.9 SE) and day 1 cria sera (22.2 mg/ml + 4.8 mg/ml SE) corroborates those of 
previous studies (23); however, here we show that all the IgG isotypes were 
represented in lacteal secretions and transferred to the neonate.  Recent studies 
implicate the FcRn, detected in mammary gland tissues, as being involved in 
transcytosis of IgG into colostrum (33).  Because this receptor is predicted to bind 
both conventional and heavy-chain IgGs, based on conserved Fc contact residues (33, 
34), we presume that HCAbs may also exploit these receptors to facilitate their 
transcytosis into colostrum as well as their uptake into neonatal serum. 
B cell development was observed as early as 5 m of gestation.  The appearance 
of HCAb+ B cells within fetal tissues coincided with that of conventional B cells.  
Since no IgM-HCAb equivalent has been described to date, and structural 
incompatibilities make isotype-switching from conventional IgM to a HCAb isotype 
implausible, it is appealing to postulate that a distinct lineage of B cells in camelids 
express BCR comprised of IgG HCAb.  In fact, Zou et. al (35) have shown 
conclusively that HCAb expression can instigate B cell development exclusive of IgM 
expression.  In alpacas, it appears that while lymphopoeisis may occur within bone 
marrow, it is the spleen that functions as the site of development for both HCAb-
producing and conventional B cells. 
Two pathways have been described for B cell development in mammals: 
classical and alternative.  The latter proceeds with the rearrangement of light chain 
genes independently of heavy chain gene rearrangement (36-39).  In human and 
mouse, the fetal liver and bone marrow serve as primary lymphoid organs for B cells 
maturation (40).  In the ruminants, it is the fetal spleen that serves as the site of B cells 
maturation (41).  This function is subsequently transferred to the ileal Peyer’s patches 
of gut-associated lymphoid tissues (GALT) during the late stages of gestation (42-44).   
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 In the sheep, IgM+ B cells appear initially in the fetal spleen by the end of the first 
trimester of gestation (41), and within the jejunum and ileum by days 65 and 68, 
respectively (45).  However, lymphoid follicle formation commences by day 75 in the 
jejunum and day 97 in the ileum (46).  The ileal B cells subsequently leave this site to 
disseminate to the secondary lymphoid organs (47, 48).  Our investigations provide 
evidence that camelid B cell development was more analogous to that of the 
ruminants.    
It is not until after 42 days of birth that optimal levels of endogenous IgGs 
were detected in cria serum.  The data correlate with those from dromedary studies (2, 
25).  We observed that maternal HCAbs were cleared more quickly than conventional 
IgGs, as it took 14 days for the HCAb isotypes to decline to 50% that of the highest 
concentrations obtained at day 1 post-partum, compared with 20 – 25 days for the 
conventional IgG isotypes.  While the levels of maternal IgG1 isotypes remained high 
in cria serum, a noticeable increase in the IgG127E10 and IgG38E1 levels could be 
detected.  This event may signify the maturity of the neonate’s immunity in response 
to environmental factors as well as vaccination.  Newborn crias are administered 
vaccinations against clostridium, rabies and tetanus at two and four months of age. 
In adult alpacas, the distribution of HCAb-producing B cells among and within 
secondary lymphoid tissues was similar to conventional B cells.  Cells that were 
positive for HCAbs were found in all the lymphoid tissues examined, including 
mucosal tissues.  The presence of HCAb+ cells within germinal centers provides 
evidence that these cells may also use this site to undergo affinity maturation and 
perhaps isotype switching.  Collectively, the mucosal surfaces encounter a vast array 
of antigens to which most of the resident lymphocytes become tolerant.  The functions 
of the B cells found within MALT Peyer’s patches and isolated lymphoid aggregates 
are distinct and in the presence of antigens undergo clonal proliferation to become 
 136
 predominantly IgA-secreting plasma cells (50, 51).  In intestinal tissues, the 
prevalence of HCAb+ cells was low; however, the presence of IgG31D1+ cells within 
Peyer’s patches may indicate that this isotype contribute significantly to mucosal 
immunity.  In spleen, it was noted that only conventional IgG126G11+ B cells populated 
marginal zone of white pulp follicles.  Marginal zone B cells are a distinct lineage of 
cells that exhibit a pre-activated phenotype and provide the first line of defense against 
blood-borne antigens (52).  These B cells respond to T-independent antigens to rapidly 
differentiate into IgM-secreting plasma cells (53).  The presence of IgG126G11+ B cells 
within marginal zones spleens implicates a role for this isotype in defense against 
blood-borne and T-independent antigens in alpacas.  Finally, terminally differentiated 
B cells become plasma cells and reside within the bone marrow. Plasma cells are 
responsible for approximately 90 % of IgG and IgA present in serum.  Our data 
indicate that HCAb-producing plasma cells also reside within bone marrow similar to 
conventional B cells. 
In aggregate, the humoral branch of camelid immune system is comparable 
with that of ruminants and other GALT animals.  We have shown that the HCAb-
producing cells develop at the same time as conventional B cells within similar 
organs.  In the adults, there is an overlap in distribution of HCAb+ and conventional B 
cells, suggestive of an overlap of immune functions.  Also, we have shown that 
conventional and heavy-chain IgGs demonstrate distinct catabolic rates in serum.  We 
postulate that the HCAb isotypes may serve to augment the antigen binding repertoire 
of conventional IgG isotypes. 
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 The overall objective of this study was to contribute to the knowledge of 
camelid HCAbs by illuminating their role in immunity, and by describing the 
ontogeny of the B cells that produce them.  The work described provides evidence that 
IgG2 and IgG3 HCAbs have distinct immunological functions.  While IgG2 was 
induced during helminth infection, an anti-viral response produced potent neutralizing 
IgG3 antibodies.  IgG2 antibodies produced by vaccination with virus demonstrated 
inferior neutralizing activities.  Overall, the expression of conventional IgG1 appeared 
not to be influenced by the nature of the pathogen.  In addition, the data revealed that 
all the IgG isotypes in serum are transferred to colostrum and subsequently to neonatal 
animals, including the heavy-chain isotypes, suggesting that HCAbs contribute to the 
passive transfer of maternal immunity.  Finally, we showed that there is an overlap in 
anatomical distribution of conventional and HCAb-producing B cells during 
development and through life.  These findings are compatible with the conclusions 
that the HCAb-producing B cells undergo development within conventional B cell 
compartments, and that they home to similar peripheral lymphoid tissues to execute 
traditional B cell functions. 
The data presented here provide evidence that B cell development in the 
camelids is similar to that of the ruminants.  Using reagents that demonstrated 
specificity for an uncharacterized B cell surface antigen (LH41 (1)), we demonstrated 
that fetal bone marrow likely served as the site for B cell lymphopoeisis.  However, 
because these cells did not stain with any of the isotype-specific mAbs, we deduced 
that B cells were not expressing the BCR in bone marrow.  Instead, the data implicate 
the spleen as being the primary organ within which both conventional and HCAb-
producing B cells undergo VDJ rearrangement, BCR expression and class-switching.  
In sheep, B cells egress the spleen and relocate to the GALT to undergo repertoire 
diversification (2).  These cells populate jejunal Peyer’s patches by mid-gestation, then 
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 ileal Peyer’s patches during the late gestational period (Reviewed in (3)).  We were 
fortunate to obtain lymphoid tissues from fetal alpacas at 5 m and 6 m of gestation.  
The distribution of B cells within the tissues was comparable in the two animals; 
however, the architecture of tissues was superior in the six month fetus.  Follicles were 
observed within fetal alpaca ileal tissues; however, these cells did not stain with the 
isotype-specific reagents.   Unfortunately, jejunal tissues had not been collected so we 
were not able to assess the prevalence of B cells within jejunal and ileal Peyer’s 
patches.  Because of the similarities of B cell distribution within lymphoid tissues at 
mid-gestation between sheep and alpaca, it seems likely that jejunal tissues would also 
stain positive for B cells. 
This work provides the foundation for additional investigations into camelid B 
cell development.  Assessment of lymphoid tissues collected from additional time 
points during gestation would provide a more comprehensive description of B cell 
development in camelids.  In addition, as more reagents become available, other 
techniques can be applied, e.g. flow cytometry, to phenotype cells collected at 
different developmental stages.  It is interesting that B cells within alpaca ileal 
follicles at mid-gestation were not identified using any of the isotype-specific reagents 
because in sheep, these cells express IgM receptors (4, 5).  To date, the existence of a 
µ equivalent of HCAbs has not been ruled out.  It is provocative to speculate whether 
B cells within ileal follicles at mid-gestation express BCR receptors that were 
undetected by the reagents used in the assays.  Finally, it would be interesting to 
characterize the reactivity of the LH41 mAbs.  Reactivity with markers expressed on 
B cell progenitors and throughout life suggests that LH41 may bind to B220 (CD45R), 
CD19 or CD21.   
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  The distributions of B cells within adult tissues indicate that HCAb-cells 
populate conventional B cell areas.  However, B cells within the marginal zones of 
adult, alpaca spleens expressed conventional IgG126G11 exclusively.  Marginal zone B 
cells are a distinct lineage of cells that display a pre-activated phenotype, and are 
positioned at the blood-lymph interface to mount rapid responses to blood-borne 
bacteria (6-8).  The data from our study suggest that we have identified an IgG isotype 
expressed by alpaca MZ B cells.  An experiment that could address this would be to 
immunize alpacas with bacterial antigens to assess whether IgG126G11 is induced and 
compare the response with that of splenectomized animals.  A predominance of 
bacteria-specific IgG126G11 and an absence of this response in splenectomized animals 
would support a MZ lineage.  In addition, B cells present in adult, ileal follicles 
expressed on the IgG31D1 isotype.  Assessments of IgG distribution in mucosal 
secretions by ELISA would a straightforward method to investigate whether this 
HCAb contributes to the protection of mucosal surfaces.  These experiments would 
serve to further clarify specialized functions of camelid conventional and heavy-chain 
IgGs. 
 It would be of interest to investigate the cytokine milieu that regulates B cell 
expression of specific IgG isotypes.  Recently, Odbileg et. al reported on the cloning, 
sequencing and analyses of cDNA encoding cytokines produced by camelids  (9-12).  
These include the inflammatory cytokines, interleukin (IL)-1α, IL-1β, IL-6, and tumor 
necrosis factor (TNF)-α; Th1 cytokines, interferon (IFN)γ, IL-2, IL-12p35 and IL-
12p40; and Th2 cytokines, IL-4, and IL-13.  In addition, cDNA sequences encoding 
the anti-inflammatory cytokine, IL-10, have also been reported.  Phylogenetic analyses 
demonstrated high homology among the cytokines produced by camelids and those 
produced by other Artiodactyls.  Future studies using recombinant forms of these 
cytokines would be useful in demonstrating how B cells are regulated to express the 
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 different heavy-chain isotypes compared to conventional IgGs.  To address this, an in 
vitro system could be designed in which B cells would be cultured in the presence of 
the various cytokines, and ask whether the different IgG isotypes are expressed in a 
cytokine-dependent manner.  The technique described in Chapter 3 has been 
optimized to separate mononuclear cells from peripheral blood.  An enriched primary, 
B cell population could be obtained and cultured in the presence of cytokines, and 
supernatant could be analyzed by ELISA using the isotype-specific mAbs.  This 
information would help to further elucidate B cell regulation in camelids and will be 
useful for improving the design of vaccines. 
 Further, it would be informative to characterize additional effector functions of 
camelid IgG isotypes.  Here, we illustrated that IgG3 antibodies were induced by a 
classical type 1 pathogen and that they were highly effective at neutralizing virus.  
This activity was shown to be C′-independent.  However, we did not precisely address 
the mechanism by which neutralization was executed.  Additional binding assays 
would have to be conducted to investigate whether neutralizing antibodies interfere 
with WNV attachment using Vero cells, a permissive cell line, or whether 
neutralization is effected at a stage downstream of attachment (13).  Also, at low 
concentrations, virus-specific IgG1, IgG3 and IgG2 enhanced the ability of WNV to 
infect FcγR-bearing cells.  This enhancement was diminished by complement.  
Experiments to ascertain that IgGs bind FcγRs could be conducted using the protocol 
described by Thrasher et. al  (14).  Immune complexes, prepared using IgG isotype-
specific mAbs, or monomeric IgGs could be incubated with FcγR-bearing cells, e.g. 
macrophages or neutrophils.  Differences in binding of monomeric IgGs or immune 
complexes observed by flow cytometric analysis would illustrate whether the different 
isotypes bind to low or high affinity receptors. 
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  When Vero cells and alpaca macrophages were inoculated with WNV, C′ did 
not significantly alter the ability of the virus to infect and replicate compatible with the 
conclusion that C′ alone was not sufficient to neutralize.  Of the three isotypes, 
neutralizing activities of IgG2 appeared to be most dependent on C′.  In four of the 
five animals that produced anti-WNV IgG2, the presence of C′ improved the 
neutralizing effects as much as eight-fold.  It would be interesting to conduct 
experiments comparing the ability of IgG1, IgG2 and IgG3 to activate the C′ cascade 
using the standard 50 % hemolytic complement assay (CH50).  Animals (n > 1) could 
be immunized to produce antibodies against sheep erythrocytes that could be affinity-
purified using chromatography techniques described in Chapter 2, prior to use in CH50 
assays. 
 Overall, the isotype specific reagents described here proved valuable in our 
investigations and will certainly be instrumental in future experiments.  Presently, we 
have seventeen mAbs that are specific for camelid IgG1, IgG2 and IgG3 isotypes.  
Mono-specific clones, 27E10, 26G11 and 8E1 discern among two IgG1 sub-isotypes 
and one IgG3 isotypes, respectively, while 1D1 binds to both sub-isotypes of IgG3.  
Clone 19D8 binds all the IgG2 sub-isotypes.  To precisely assess the immunological 
functions of distinct sub-isotypes, further characterization of the mAbs will have to be 
conducted.  There are five additional anti-IgG2 mAbs that could be tested for sub-
isotype specificity.  IgGs purified over 1D1-columns from 8E1-depleted sera can be 
used to immunized mice in to produce hybridomas that express mAbs specific for the 
newly described IgG3.  Finally, we have yet to determine which sub-isotypes of IgG1 
and IgG3 are recognized by the mAbs, hence the temporary nomenclature IgG127E10, 
IgG126G11, IgG38E1 and IgG31D1.  Collaborative efforts between Appleton and 
Muyldermans propose experiments to express characterized γ gene sequences and use 
these proteins in assays to determine isotype-specificity of the mAbs. 
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  In summary, the work presented here has advanced our understanding of the 
functional significance of camelid HCAbs as well as fundamental knowledge of B 
cells in immunity.  The clinical importance of this work is that we have set the 
foundation for evaluating IgG responses induced by infection and vaccination, which 
is applicable in designing vaccines and conducting trials to assess their efficacy in 
conferring protection.  Also, simple, serologic, diagnostic assays can be designed to 
document exposure of animals to specific pathogens.    
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